Annual Report 2011. English Version by Blagojevic, S. & Wild, C.
Institut für Health Technology Assessment
der Ludwig Boltzmann-Gesellschaft
 
Annual Report 
2011 
 

 Annual Report 
2011 
 
Vienna, February 2012 
Ludwig Boltzmann Institute for Health Technology Assessment 
Authors: DI Smiljana Blagojevic 
 PD Dr. phil Claudia Wild  
 & the LBI-HTA Team 
Vienna, February 2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTHEAD 
Editor and owner: 
Ludwig Boltzmann Gesellschaft GmbH 
Nussdorferstrasse 64, 6. Stock, A-1090 Vienna 
http://www.lbg.ac.at/gesellschaft/impressum.php 
Responsible for the content: 
Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA) 
Garnisongasse 7/20, A-1090 Vienna 
http://hta.lbg.ac.at/ 
The annual reports are available on the web page: 
http://hta.lbg.ac.at/de/content.php?iMenuID=55 
© 2012 LBI-HTA – All Rights reserved 
 LBI-HTA | 2012 3 
Table of Contents 
Table of Contents ....................................................................................................................................................3 
1 The Institute – an Overview.............................................................................................................................5 
1.1 Partners.............................................................................................................................................................. 5 
1.2 Committees ....................................................................................................................................................... 7 
1.3 Staff & Human Resources Development ....................................................................................................... 9 
1.4 Infrastructure .................................................................................................................................................. 14 
1.5 Highlights of the Year ................................................................................................................................... 15 
1.6 Research Programme ..................................................................................................................................... 20 
2 Research............................................................................................................................................................23 
2.1 Projects and Scientific Support of Decision-Making ................................................................................. 23 
2.2 Publications..................................................................................................................................................... 56 
2.3 Participation in Scientific Meetings............................................................................................................. 64 
3 Scientific Co-operations..................................................................................................................................67 
4 Other Activities ...............................................................................................................................................71 
5 Outlook.............................................................................................................................................................73 
 
 
Table of Figures 
Figure 1.2-1: Organigramm...................................................................................................................................................... 7 
Figure 1.2-2: POP database..................................................................................................................................................... 16 
Figure1.2-4: LBI-HTA 5-year anniversary .......................................................................................................................... 18 
Figure 1.2-5: Business Run..................................................................................................................................................... 19 
Figure 1.2-6: Narrenturm Wien & Restaurant Stomach.................................................................................................... 20 
Figure 2.1-1: “Parent-Child-Care New” programme.......................................................................................................... 43 
Figure 2.1-2: Download HTA-Newsletter 2009, 2010 & 2011 .......................................................................................... 45 
Figure 2.1-3: Website hits 2009, 2010 & 2011...................................................................................................................... 49 
Figure 2.1-4: Website visits 2011 ........................................................................................................................................... 49 
 

 LBI-HTA | 2012 5 
1 The Institute – an Overview 
The Ludwig Boltzmann Institute for Health Technology Assessment (LBI-
HTA) was formally founded on March 2006 and is intended to operate for a 
period of seven years. Therefore, 2011 was the 5th year of the institute’s opera-
tional activity. Evaluation regarding its continuation until 2013 took place in 
Spring 2009. The evaluation results were (fortunately) very positive. 
In 2011, the annual budget of the Ludwig Boltzmann Institute for Health 
Technology Assessment – funded by the Ludwig Boltzmann Society and in-
stitutional partners – was € 815,000. The (additional) third party funding of € 
75,000 amounted to approximately 8% of the total budget.  
1.1 Partners 
In line with the research policy of the Ludwig Boltzmann Society, the insti-
tute focuses on translational research. The research programme requires 
strong emphasis on applicable short-term or medium-term results. By setting 
up partnerships between research-producing and research-applying organisa-
tions or institutions, the quick transfer of research results is guaranteed. 
The partner institutions of the Ludwig Boltzmann Institute for Health 
Technology Assessment are stakeholders in health care administration (2), 
responsible bodies of public hospitals (2) and private universities (1).  
 
TILAK/ Tiroler Landeskrankenanstalten GmbH 
Anichstraße 35, 6020 Innsbruck 
http://www.tilak.at 
KAGES/ Steiermärkische Krankenanstalten GmbH 
Stiftingtalstraße 4-6, 8010 Graz 
http://www.kages.at 
 
2011:  
5th year of existence 
evaluation regarding 
continuation until 2013 
total budget 
institutional partners 
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BMG/ Bundesministerium für Gesundheit  
Radetzkystraße 2, 1030 Wien  
http://www.bmg.gv.at 
HVB/ Hauptverband der österreichischen Sozialversicherungsträger  
Kundmanngasse 21, 1030 Wien 
http://www.hauptverband.at 
(since 2008) 
UMIT/ Private Universität für Gesundheitswissenschaften, Medi-
zinische Informatik und Technik 
Institut für Public Health, Medical Decision Making und HTA 
Eduard Wallnöfer-Zentrum I, 6060 Hall  
http://www.umit.at 
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1.2 Committees 
The LBI-HTA is supported by two committees, namely the Board of Trus-
tees and the Scientific Advisory Group (SAG). 
Figure 1.2-1: Organigramm 
Whereas the LBI-HTA’s research programme provides a general methodo-
logical background, agenda setting for current projects is the task of the 
Board of Trustees, which is composed of one representative from each insti-
tutional partner. 
 
KAGES: Mag. Dr. August Gomsi (Chair) 
TILAK: Univ. Prof. Dr. Wolfgang Buchberger 
BMG: Dr. Wolfgang Ecker resp. Dr. Silvia Türk 
HVB: Dr. Gottfried Endel 
UMIT: Univ. Prof. Dr. Uwe Siebert 
LBG: Mag. Claudia Lingner  
In 2011, two Board meetings (at LBI-HTA) took place: 
 1st Board meeting: 05/04/2011 
 2nd Board meeting: 27/09/2011 
6 board members 
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The first board meeting in 2011 dealt with the issues of the budget and the 
current scientific programme, the status of LBI-HTA 2013+, as well as the 
topic identification and prioritisation for the work programme 2011 to 2012. 
The second board meeting in 2011 included reports from the Institute Di-
rector and Deputy, as well as much room for discussions with and inputs 
from the Board. The following topics were addressed:   
 Budget  
 Current scientific programme 2010/11  
 Status of the Institute – 2013+ 
The Scientific Advisory Group (SAG) gives scientific support and is se-
lected – with equal weighting – by the Ludwig Boltzmann Society and the 
members of the Board of Trustees. The SAG is composed of the following 
members: 
 Univ. Prof. Dr. Finn Borlum Kristensen /DK (Chair) 
 Univ. Prof. Dr. Alistair Gray /UK 
 Univ. Prof. Dr. Jürgen Windeler /D 
 Dr. Dagmar Lühman /D 
 Dr. Irina Cleemput /BE (since 2010) 
The fifth meeting of the Scientific Advisory Group (WB) was held (at LBI-
HTA) on 24/11/2011.  
The morning began with the Institute Director’s brief summary of the scien-
tific activities conducted in the subsequent year. Afterwards, lectures and 
discussions were held in four topic areas. 
Topic: Methodological challenge – systematic review of systematic reviews 
 Review Varicosis – one approach (Marisa Warmuth) 
 Review MEL/hospital interventions – another approach (Anna 
Nachtnebel) 
 Methodological standards at KCE (Irina Cleemput) 
Topic: Relation – HTA & Health Services Research 
 HSR as Part of HTA (Finn Borlum Kristensen) 
 Use of routine data (Ingrid Zechmeister-Koss) 
Topic: Piggy-back studies 
 Challenges with piggy-back studies (Alistair Gray) 
 Piggy-back study in evaluating juvenile psychiatry (Ingrid 
Zechmeister-Koss) 
 
 
 
 
 
1st board meeting 
5/04/2011 
 
2nd board meeting  
27/09/2011 
5 SAG Members  
last meeting of the 
Scientific Advisory 
Group:  
24/11/2010 
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Topic: Organisational procedures and challenges 
1.) From assessment to appraisal to recommendations: Transparent proc-
esses? 
 MEL /hospital interventions - 3 years of experience contrasting rec-
ommendations with decisions (Claudia Wild) 
 From assessment to the formulation of recommendations at 
KCE (Irina Cleemput) 
2.) Inclusion of peers and public: How and when? (Irina Cleemput) 
 Peer-review: Expert inclusion – at what stage, identification, selec-
tion process, handling / acceptance of comments, etc. 
 Public consultation: Identification, at what stage, procedures, 
handling / acceptance of comments 
3.) Prioritisation of topic selection:  
 Criteria and weighing of policy relevancy / urgency (Irina Cleem-
put) 
1.3 Staff & Human Resources Development 
As an interdisciplinary institute, the organisation of work is guided by pro-
fessionally-assigned, topic-specific project management. Again, the compul-
sory weekly team meeting (Tuesdays at 2 p.m.) proved to be essential and 
necessary for effective team communication at the LBI-HTA. 
Director & Head of Department ‘High Tech in Hospitals’: 
 Claudia Wild, Priv.-Doz. Dr. phil. 
Research Background: Communication Science, Psychology, Politi-
cal Science, Social Medicine 
Deputy Director & Head of Department ‘Health Economics’: 
 Ingrid Zechmeister-Koss, Dr. rer. soc. oec., MA 
Research Background: Health Economics 
Head of Department ‘Public Health & Health Services Research’: 
 Brigitte Piso, Dr. med., MPH 
Research Background: Medicine, Public Health  
Office Assistant: 
 Smiljana Blagojevic, Dipl.-Ing.  
Background: Agronomy 
Assistant-to-the-Director & Head of Science Communications: 
 Gerda Hinterreiter, Mag. rer. soc. oec. (until 30/11/2011) 
Background: Medical Sociology, Communication  
Information Specialist: 
  Tarquin Mittermayr, BA (Hons) 
organisation of work 
team members  
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Researchers: 
 Marisa Warmuth, Dr. med., MIPH 
Research Background: Medicine, Public Health 
Senior Researcher 
 Anna Nachtnebel, Dr. med., MSc PH 
Research Background: Medicine, Public Health 
Senior Researcher 
 Roman Winkler, Dr. phil, MSc  
Research Background: Communication Science 
Senior Researcher 
 Stefan Mathis-Edenhofer, Dr. med., Dipl.-Ing.  
 Research Background: Medicine, Biomedical Informatics 
Senior Researcher 
 Philipp Mad, Dr. med. 
Research Background: Medicine 
Senior Researcher 
 Philipp Radlberger, Mag. rer. soc. oec. (until 30/04/2011) 
Research Background: Health Economics 
Junior Researcher 
 Katharina Hintringer, BA 
Research Background: Social- and Health Management 
Junior Researcher 
Schumacher Ines, MPH (freelance researcher) 
Research Background: Public Health 
Junior Researcher 
 Nikolaus Patera, Mag. rer. soc. oec. (freelance researcher) 
Research Background: Health Policy/Health Services Research 
Junior Researcher 
Layout & Graphic Design: 
 Darko Blagojevic 
Compulsory Trainees:  
 Veronika Häussler (01/03/2011 until 30/06/2011) 
Research Background: Applied Business Administration 
 Florian Schramm (8/08/2011 until 31/09/2011) 
Research Background: Health Care Engineering/eHealth 
 Johannes Gugerbauer (16/08/2011 until 31/09/2011) 
Research Background: Health Care Engineering/eHealth 
 Bernd Wimmer (01/09/2011 until 30/09/2011) 
Research Background: Sociology 
Volunteer Trainees:  
 Jone Gerdvilaite (from 01/04/2011 until 30/06/2011) 
Research Background: Health Management  
 
currently (Dec 2011)  
14 persons in total 
 (=11 FTE) 
 
many assistants 
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 Stefan Fischer (01/05/2011 until 31/08/2011, 01/10/2011 until 
30/03/2012) 
Research Background: Health Economics 
 Judit Erdös (01/10/2011 until 31/12/2011) 
Research Background: Health Management 
Literature Acquisition: 
 Johannes Setz 
 Laura Brückner 
 Thomas Stumpner 
Furthermore, there are also external experts working on several projects for 
the LBI-HTA. In 2011 those were: 
 Florian Endel 
Research Background: Data Engineering and Statistics 
 Elisabeth Hintringer, Mag.phil. 
Research Background: Health Management 
 Tim Johansson, Dr.  
Research Background: Public Health 
 Caroline Hepperger 
Research Background: Business Administration/Health Sciences  
Staff members who left the LBI-HTA in 2011: 
Philipp Radlberger worked as a researcher at the LBI-HTA in the field of 
Health Economy (40 hrs./week) until 30/04/2011, when his doctorate position 
ended.  
Gerda Hinterreiter worked as the Assistant to the Institute Director and was 
responsible for scientific communication until 30/11/2011. She left the Insti-
tute to take on a professional position closer to her hometown in Upper Aus-
tria.  
Besides the organisational development of an interdisciplinary research insti-
tute, professionalisation and specialisation of the team members are key is-
sues. Becoming an interdisciplinary research institute involves the exchange 
of perspectives and methodologies, cooperation during projects, internal 
presentations and discussions, and internal evaluations in order to ensure 
high-quality work.  
With the goal of professionalising management, the Ludwig Boltzmann Ge-
sellschaft regularly initiates Institute Director training retreats. Claudia 
Wild attended the executive training session “Personnel Develop-
ment/Career Development in Pöllauberg,” held at the Seminarhotel Pöl-
lauberg in Styria from 07.-09.09.2011. In addition, she participated in com-
munication training at the “Schule des Sprechens” in Vienna between Sep-
tember and December 2011. 
Individual employees attended the following advanced training courses: 
 24.-29/01/2011: 6-day certificate course “Winter School in Clinical 
Epidemiology”, UMIT/Hall in Tyrol (Gerda Hinterreiter, Stefan 
Mathis-Edenhofer, Anna Nachtnebel, Nikolaus Patera, Philipp 
external experts 
objectives: 
professionalisation, 
specialisation 
executive management 
training 
specific training for 
individuals  
epidemiology 
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Radlberger, Ines Schumacher, Marisa Warmuth, Roman 
Winkler, Ingrid Zechmeister-Koss, Katharina Hintringer)  
 01/12 to 02/12/2011: “Benefit Evaluation on the Basis of Patient 
Preferences: Patient-Reported Outcomes (PROs) and Discrete 
Choice Experiment (DCE)”, GÖG/Vienna (Marisa Warmuth, 
Stefan Mathis-Edenhofer, Ines Schumacher, Anna Nachtnebel) 
 6/11/2011: Pre-Conference Workshop “Reimbursement Systems in 
Europe”, ISPOR 14th Annual European Congress (Katharina Hin-
tringer) 
In the scope of his doctorate study of Economic Policy at the Vienna Univer-
sity of Economics and Business, Philipp Radlberger attended the research 
seminars “Social Policy”, “Topics of International Trade”, as well as “Im-
mersion in Qualitative Methods” in Winter Semester 2009/10, Summer Se-
mester 2010 and Winter Semester 2010/11. 
Since October 2009, Katharina Hintringer has been a master student of 
“Health Sciences” at the UMIT – The Health and Life Sciences University 
in Hall/Tyrol, where her major focus is on Public Health. 
Philipp Mad, researcher (part-time) in the specialist field of medicine, suc-
cessfully completed his residency as a paediatrician.  
The Ludwig Boltzmann Institute for Health Technology Assessment and its 
staff are members of the following international and national organisations: 
 HTAi (Health Technology Assessment international) 
 INAHTA (International Network of Health Technology Assess-
ment) 
 EUPHA (European Public Health Association) 
 DNEbM (German Network for Evidence-based Medicine) 
 Society for the Promotion of Technology Assessment in Health Care 
(Health Technology Assessment)  
 ÖGPH (Austrian Society for Public Health) 
 EuroScan (International Information Network on New and Emerg-
ing Health Technologies) 
 EUnetHTA (European Network for Health Technology Assess-
ment) 
continuing higher 
education: 
 
1 current doctorate  
1 current master  
1 resident paediatrician 
institutional 
memberships 
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Claudia Wild is a member of:  
 OSR /Supreme Medical Council (Meetings on 02//04/2011 and 
12/11/2010) 
 Oncology Advisory Board of the Austrian Federal Ministry of 
Health (meetings held on 14/10/2011 and on 12/12/2011) 
 Project advisory group of the EBM Working Group of the Associa-
tion of Austrian Social Security Organisations  
 Scientific Advisory Committee of DAHTA@DIMDI (Meetings on 
15/02/2011 and 09/11/2011)  
 International Advisory Boards of the Journal for Evidence, Continu-
ing Education and Quality in Health Care (ZEFQ) 
 Transparency International, Austrian Chapter, Workgroup Health 
Care 
 Advisory Board “Health Statistics” by Statistic Austria 
 
In addition, Claudia Wild carried out the following scientific advisory activi-
ties in the year 2011:  
 Jury member of the German Cancer Aid for research funding of ma-
jor multi-year projects on “Cancer Prevention”. 
 Member of the Poster Jury at the 2011 German EbM Network Con-
ference in Berlin. 
 Scientific advisor for the 2012 German EbM Congress on “Complex 
Interventions” in Hamburg/2012. 
 Participated in the expert round table for the working group on 
“More Transparency and Reduction of Corruption and Extraneous 
Influences” of the Conflict of Interest (CoI) sub-working group at 
the Social Insurance Institution (SVB), Vienna, 11/07/2011.  
 Participated in the expert discussion on the Swiss study concerning 
“Methods of Benefit Evaluation in Switzerland and Europe“, Dr. 
Florian Gutzwiller, Institute of Pharmaceutical Medicine (ECPM), 
University of Basel, 25/08/2011. 
 Participated in an expert discussion with members of the Scientific 
Advisory Committee of the Swedish Parliament, Dr. Helene Limén, 
23/03/2011. 
Ingrid Zechmeister-Koss is a member of the Austrian Society for Public 
Health and was active in 2011 in the scope of 
 The Dialogue for Children’s Health, Task Force (Austrian Federal 
Ministry of Health, 16/03/2011), as well as  
 The National HTA Strategy and the Methods Manual at Gesund-
heit Österreich GmbH/GÖG (30/03/2011, 14/06/2011, 21/09/2011). 
 
individual memberships: 
OSR,  
Oncology Advisory 
Board 
scientific council of 
bioethics, 
 
scientific advisory 
committee:  
EBM-HVB,  
DAHTA, ZEFQ 
 
advisory board:  
Statistik Austria,  
jury and advisory 
activities 
The Dialogue for 
Children’s Health/BMG 
nat. HTA Strategy / 
GO¨G 
MEL / BMG 
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Brigitte Piso is a Member of the Board of the Austrian Society for Public 
Health (ÖGPH) and a member of the European Public Health Association 
(EUPHA). 
In 2011, Brigitte Piso was additionally a member of  
 The Dialogue for Children’s Health, Task Force on High-Risk 
Pregnancy/High-Risk Birth and the Consequences (Austrian Fed-
eral Ministry of Health [BMG], 10/3/2011). 
 The “Prevention” working group for the Development of a National 
Cancer Plan in Austria (Austrian Federal Ministry of Health 
[BMG], 19/1/2011, 9/3/2011, 11/5/2011). 
In 2011, Marisa Warmuth was a member of  
 The Dialogue for Children’s Health, Task Force on High-Risk 
Pregnancy/High-Risk Birth and the Consequences (Austrian Fed-
eral Ministry of Health [BMG]). 
In 2011, Roman Winkler was a member of the  
 The Dialogue for Children’s Health, Task Force, the Psychosocial 
Health Working Group (BMG, 13/01/2011, 07/03/2011, 29/04/2011).  
Stefan Mathis-Edenhofer is a member of the Austrian Computer Society 
and the German Network for Health Services Research. 
Since 2010, Anna Nachtnebel has been a member of the European Horizon 
Scanning Network “EuroScan” (International Information Network on New 
and Emerging Health Technologies). In 2011, she was a member of  
 The “Epidemiological Representation, Cancer Statistics and 
Documentation” working group for the Development of a National 
Cancer Plan in Austria (ÖSTAT, 23/02/2011, 12/04/2011, 
21/10/2011).  
Katharina Hintringer is a full student member of the Academic Senate at the 
UMIT – The Health and Life Sciences University in Hall/Tyrol.  
Philipp Mad is a member of the European Pathway Association  
(www.e-p-a.org).  
Tarquin Mittermayr is a member of the European Association for Health 
Information and Libraries (EAHIL).  
 
Gerda Hinterreiter is a member of the Austrian Society for Public Health 
(ÖGPH).  
1.4 Infrastructure 
The office of the LBI-HTA (279 m² in total) consists of seven separate rooms 
and a 70 m² library/seminar room. At the end of 2010, the institute was 
equipped with 16 personal computer workstations. No further additions are 
planned for 2012. 
Austrian Society for 
Public Health (O¨GPH) 
European Public Health 
Association (EUPHA) 
The Dialogue for 
Children’s Health  /BMG 
Oncology Advisory 
Board Working Group 
The Dialogue for 
Children’s Health /BMG 
German Network for 
Health Services 
Research  
Oncology Advisory 
Board Working Group 
EuroScan 
UMIT Academic Senate 
European Pathway 
Association (EPA) 
European Association 
for Health Information 
and Libraries (EAHIL) 
Austrian Society for 
Public Health (O¨GPH) 
office space and 
equipment 
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During the past year, the LBI-HTA library has increased its holdings to 780 
monographs. The Institute currently subscribes to eight print periodicals 
and has access to 16 electronic periodicals, as well as the important medical 
and scientific databases Ovid-Medline, Embase, Scopus and UpToDate. 
As one of the LBI-HTA goals is to provide long-term and free access to its 
publications in the Internet, the administration of the document server 
(http://eprints.hta.lbg.ac.at) was also a major work focus at the library this 
year. The document server offers extensive search possibilities in English 
and German. In addition to this very important distribution path for knowl-
edge transfer, the office of the Centre for Reviews and Dissemination (CRD) 
in York regularly receives the bibliographic data of LBI-HTA publications. 
Owing to this cooperation, the Institute’s publications are entered into the 
HTA database of the CRD and can be accessed at 
http://www.crd.york.ac.uk/crdweb. Furthermore, the document server is syn-
chronised monthly with the global online library network WorldCat, ena-
bling LBI-HTA publications to be searched, resp., accessed via the digital 
WorldCat archive (http://www.worldcat.org/). 
Tarquin Mittermayr is responsible for the institute's library and provides 
systematic literature searches for the LBI-HTA's scientific staff.  
1.5 Highlights of the Year 
In the scope of “Joint Action (1) EUnetHTA 2010-2012” on behalf of a 
longer-term and therefore sustainable EU cooperation network funding, the 
LBI-HTA is leading the Work Package 7B, which is pursuing the decided 
goal to reduce the high degree of redundancies in EU-wide HTA production, 
as well as to support cooperative efforts. For this purpose, a database of all 
planned and ongoing assessments of the EUnetHTA partner organisations 
(POP database) was developed. Initially – until the middle of 2011 – a sim-
ple Excel list, it was transformed into a database in August in close collabora-
tion with the EUnetHTA IT Work Package 6 partners KCE /Belgian Health-
care Knowledge Center, as well as the DIMDI / German Institute of Medical 
Documentation and Information, and was equipped with functions such as 
“sort” (according to topic, country, institution) or “search” (according to 
MeSH, etc.). Further function enhancements will follow in 2012.  
 
library 
8 subscriptions 
775 monographs 
 
 
document server 
synchronised with 
  
WorldCat online library 
network 
international 
cooperation: EUnetHTA 
Joint Action 2010-2012 
LBI-HTA leads WP 7B 
 
reduction of overlaps 
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Figure 1.2-2: POP database 
This POP database can only be accessed by “contributing” EUnetHTA part-
ners, meaning those partners who regularly update their database entries: 
“give and take” is the access principle here. Currently, 1,100 ongoing, 
planned or recently completed projects of 42 EUnetHTA partner organisa-
tions from 24 European countries are listed. The presumed and observed re-
dundancies can now be quantified: a 13% overlap of identical topics, particu-
larly in the fields of Pharmaceutics / New Drugs and Technologies / High 
Tech Interventions, and a 30% overlap of similar themes in the same indica-
tion areas (dementia, ADHD, rheumatism, etc.). 
In 2011, an application for a further “Joint Action (2) EUnetHTA 10/ 2012-
09/2015” was submitted and approved. The LBI-HTA will also take on a 
prominent position here, namely as the co-leader with the Dutch CVZ / Col-
lege voor zorgverzekeringen in Work Package 5 on “Testing partners’ capac-
ity to apply the HTA Core Model for Rapid Assessment in collaborative 
production of HTA information for national adaptation and reporting”. 
Whereas the creation of structures for transnational, mutual HTA produc-
tion was the content of EUnetHTA Joint Action 1, the actual production will 
be the main activity in EUnetHTA Joint Action 2. 
 
As spin-offs from the EUnetHTA POP database, LBI-HTA initiatives for 
cooperation with other EUnetHTA partner organisations were established: 
on the one hand, in the scope of the “Horizon Scanning in Oncology” pro-
gramme; on the other hand, “Calls for Collaboration” in the scope of the an-
nual MEL / Assessment of Individual Medical Services. It was conducted 
as an active information brokering measure for topics relevant to Austria. In 
total, 6 new medications and 1 high-tech technology were assessed in 2011 in 
cooperation with other European HTA institutions (AHTAPol/PL; ULSS-
20; UVEF / Reg. Veneto; AGENAS / IT; Institute of Pharmacology Bremen / 
GER; Agency for Quality and Accreditation in Health; Department for De-
velopment, Research and Health Technology / CR, etc.). Working in English 
or bi-lingually is thereby a precondition. 
 
POP database 
 
13% overlap of identical 
HTA projects and 30% 
of similar HTA projects 
EUnetHTA  
Joint Action 2  
10/ 2012-09/2015 
approved 
EUnetHTA spin-offs: 
collaborations with 
oncologica and high-
tech interventions:  
a total of 6 in 2011 
working in English or 
bilingually  
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Figure 1.2-3: Examples of cooperation in the evaluation of new oncologica  
 
The German-Austrian cooperation was successfully continued with the 
Medical Service of the Central Association of Health Insurance Funds / MDS 
in the area of “NUB / New Examination and Treatment Methods” (GER) 
and “MEL / Assessment of Individual Medical Services” (AUT). The 
MEL assessments of the LBI-HTA also led to a series of scientific publica-
tions in 2011. 
In addition to the already established programme lines of new oncologica as-
sessment and the assessment of individual medical services in hospitals, we 
have increasingly devoted ourselves to the methodological challenge of the 
“Assessment of Complex Interventions”. Complex differ from simple in-
terventions that not singular interventions, but rather intervention bundles 
interact in specific implementation contexts and have to find socio-medical 
consideration. On the one hand, a LBI-HTA team of four scientists also 
worked in the second project year of the “Parent-Child-Care_New” project 
on the deeper examination of single aspects (preterm birth, IT applications, 
outreach services, budget impacts). On the other hand, the assessment of 
outpatient cardiac rehabilitation went into its third project year. We began 
with the assessment of occupational therapy in individually selected indica-
tion areas in 2011 and will continue in 2012. In the field of physical medi-
cine, we conducted the first orientating reviews on “physical therapy” and on 
“training therapy”. Besides the contentual methodological challenges (spe-
cific endpoints in the different indications), the summary of reviews (Review 
of Reviews) is a methodological topic that we also addressed at the meeting 
of the Scientific Advisory Group. Avoiding redundancies by not repeatedly 
drawing upon the assessment of primary studies is an issue that is gaining 
relevancy not only in small HTA institutions such as the LBI-HTA, but also 
in the well-resourced institutions. 
NUB-MEL (GER-AUT) 
cooperation continued 
methodological 
challenge: assessment 
of complex 
interventions 
 
Parent-Child-Care_New 
outpatient cardiac 
rehabilitation 
occupational therapy 
physical therapy 
 
 
methodological 
challenge: Review of 
Reviews 
LBI-HTA,  
AHTAPol &  
UVEF (Reg. Veneto): 
 
Eribulin (Halaven®) as third- or 
late- line monotherapy for advan-
ced/metastatic breast cancer  
July 2011 
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Not least, we also continued the empirical studies of health services re-
search, resp., accompanying research in 2011 through our own primary 
studies in the fields of child and adolescent psychiatry and outpatient cardiac 
rehabilitation.  
In addition to the actual scientific preparation of content, the public presen-
tation (scientific communication) and the public discourse aimed at getting 
those interested and those affected involved the acceptance and credibility of 
HTA are important. Therefore, the conference on “Parent-Child Care - Chal-
lenges and Perspectives” was held in conjunction with the Federal Ministry 
of Health / BMG on 6 December 2011. 
Besides the substantive work, two further events stood at the centre of our at-
tention in 2011. Not only did we celebrate the five-year anniversary of the 
Institute at the XPEDIT Warehouse, but also the 100th issue of the HTA-
Newsletter. We were able to share our joy with approx. 50 invited guests. 
Figure1.2-4: LBI-HTA 5-year anniversary 
In 2004, the Ludwig Boltzmann Society (LBG) laid out plans for the creation 
of new Institutes. It decided that the “new” LBG Institutes would exist for a 
period of 7 years under the umbrella of its academic but non-university-
based research institution, in order to  demonstrate their benefit to transla-
tional research to the society’s partners within that time period.  
As the LBG offered those Institutes that had proved to be successful in the 
scope of the interim evaluation after four years (LBI-HTA: 2009) the option 
of a second period under certain conditions, efforts in 2011 were devoted to 
the strategy development for a second period (2013+).  
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Co-financing beyond 2013 requires:  
1. The handover of the Institute to an alternative legal representative, 
as well as the withdrawal of LBG funding during the second period.  
2. The handover must be pre-arranged; the approach to the timely 
withdrawal of the LBG is negotiable. The total sum made available 
by the LBG is non-negotiable.  
3. Although the legal representative – despite the co-financing of the 
LBG – may/ought to be another organisation, the LBG logo should 
continue to be used throughout the co-financing period. 
4. Before initial negotiations can begin, “Letters of Intention” from 
the new legal representative must be presented.  
On 18 October 2011, the LBI-HTA received an on-site visit: The LBG / 
Ludwig Boltzmann Gesellschaft made negotiations concerning a possible 
second period conditional upon an additional “critical look from outside” to 
the LBI-HTA and the future framework conditions and requirements. Three 
experts (Bert Boer / CVZ – NL, Raf Mertens / KCE – BE and Peter Ko-
lominsky- Rabas / earlier IQWiG, now PH Erlangen – GER) from Euro-
pean social insurance countries visited the LBI-HTA in order to advise the 
LBG. The advisory paper was also brought to the knowledge of the future 
partners. 
Every year in April, we go on a one-day topic retreat in order to divide and 
discuss the working programme of the following year amongst the staff. In 
addition to the work, a hike is also part of the programme. This year’s LBI-
HTA topic retreat on 26 April was unfortunately washed out due to the 
weather, so we “only” remained on the Institute premises.  
Figure 1.2-5: Business Run  
For the fun of collective movement, 2 three-person teams of the LBI-HTA 
(Marisa Warmuth, Roman Winkler, Smiljana Blagojevic, Ines Schumacher, 
Nikolaus Patera and Florian Schramm) took part in the 12th Wien Energie 
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Business Run on 22 September 2011. Proud, somewhat relieved and happy, 
the six received their medals at the finish line. 
Further, we said goodbye to two colleagues (Philipp Radlberger: on 24 
March; Gerda Hinterreiter: on 22 November), and naturally celebrated the 
successful medical specialist exams of Philipp Mad (8 November).  
The LBI-HTA Christmas party took place on 2. December 2011, beginning 
with a guided tour of the team through the Federal Pathologic-Anatomical 
Museum in Vienna, and ending with a comfortable evening at the restaurant 
“Stomach”. 
Figure 1.2-6: Narrenturm Wien & Restaurant Stomach 
Stefan Mathis-Edenhofer became the father of little Leonard on 16/09/11. 
We also celebrated this special occasion fittingly.  
1.6 Research Programme 
The work programme of the LBI-HTA consists of five programme lines, 
which will be briefly described. All projects will be explained in Chapter 2 
(Research), within the context of the different programme lines. 
Comprehensive Assessments of Health Interventions & Evidence-
Based Health Services Research 
HTA can now look back on 20 years of methodological developments and in-
ternational harmonisation. “Traditional” assessments answer questions on 
new/innovative or established medical interventions such as  
 Is the intervention effective, does it work? 
 For whom, which subgroup of patients? 
 At what cost? 
 How does the intervention compare with alternatives? 
Unlike traditional HTA, evidence-based health services are still young, but 
are based on the same basic research principles: systematic literature search 
and analysis, transparent presentation of sources, process and result, as well 
as interdisciplinary perspectives. In contrast to the results from the critical 
appraisal of medical interventions, the results from health services research 
are deeply anchored in the health systems concerned and cannot be as easily 
other events/ 
parties 
farewells, Christmas 
party,  
births 
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transferred into other systems. The research field of evidence-based planning 
follows the approach of distinguishing between demand and need, and of 
critically questioning the actual utilisation of health services.  
For that reason, the LBI-HTA, as an HTA institute in a small country, is de-
voted to bringing international HTA into the national context and to further 
developing methods of evidence-based health services research. 
Scientific Support of Health Policy and Decision-Maker Networks 
Policy-relevant decisions are traditionally reached on the basis of a consensus 
of high-ranking experts in boards and committees. This process of exclu-
sively expert-based (so-called eminence-based) decision-making is highly 
prone to bias, conflict of interests and doctrine. It is the aim of evidence-
based support to decision-making to collect and present recent research re-
sults and to provide a more rational and transparent input to the process of 
health policy decision-making, independent of influences from interest 
groups. The aim is to shape the process in the long term by systematically 
questioning marketed information and by asking for sound evidence. 
It is the task of the scientific support of health policy and decision-maker 
networks to react rapidly to demand and to present the evidence to decision-
makers in a transparent and readable format. 
Health Technology Assessment in Hospitals 
The informal “HTA in Hospitals” network consists of a group of about 20 
high-ranking decision-makers (medical directors and quality managers) from 
almost exclusively Austrian hospital cooperation. The network meets twice a 
year (June and October) in order to obtain informative HTA input into 4 key 
topics, to discuss them and to exchange ideas on regulation and reimburse-
ment issues. 
The task of the LBI-HTA is to coordinate the meetings, to request and col-
lect current topics and to prepare the presentations. The format of the meet-
ings is for each topic to be presented from the HTA perspective and by an 
invited clinical expert, which subsequently leads into a structured discussion.  
Scientific Decision Support of the Health Ministry 
It is the task of the LBI-HTA to provide - upon request - scientific support to 
different committees of the Austrian Health Ministry (BMG, 
http://www.bmg.gv.at): 
 to support the Medical Advisory Group in the maintenance of the 
Austrian medical procedure classification (Austrian DRG Cata-
logue) with evidence analysis of new/innovative or established 
medical interventions. 
 to react to information enquiries in the Supreme Health Council 
(advisory committee of the Health Minister). 
Public Understanding and Research Transfer 
Quite often – steered by early media coverage – the demand for 
new/innovative health care interventions emerges even before market ap-
proval or reimbursement. “Public understanding” is both the transfer of 
knowledge about market forces and about methods for critically questioning 
programme line 2 
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the evidence presented on effectiveness and cost-effectiveness, appropriate-
ness, and methodological support for the differentiation between new and 
innovative interventions. “Public understanding” is meant to contribute to a 
better understanding of true effectiveness and, at the same time, to a democ-
ratic shaping of benefit packages. 
The intention of “public understanding and research transfer” is to build up 
– through presentations, seminars, monthly newsletters, a user-friendly web-
site and search support – a critical mass of patients, journalists, representa-
tives of the health administration, academia, etc., that questions the informa-
tion presented and asks for sound evidence before decision-making. 
HTA Implementation: Development and Informing on Effective Policy 
Instruments 
Evidence for the effectiveness and cost-effectiveness of numerous technolo-
gies and interventions can often only be presented after market approval and 
several years’ use under real clinical conditions. However, even then, ineffec-
tive technologies are widely spread and applied. Since it is ethically not justi-
fiable to withhold true medical innovations from patients, and because 
pseudo-innovations absorb a lot of resources, taking new technologies under 
“surveillance” or “limited application” at specific medical centres is more 
and more frequently considered. Consequently, final decisions on reim-
bursement are made only after patient-relevant outcome data become avail-
able. 
Methods for limited application and the assessment and appraisal of tech-
nologies and interventions after having obtained patient-relevant outcome 
data are still young. In this programme line, they will be further developed 
and applied. 
International Cooperation / HTA Best Practice  
International cooperation and collaboration, particularly within the Euro-
pean Union, is becoming increasingly important in order to avoid redundan-
cies in the assessment of medical technologies prior to reimbursement or in-
clusion in public benefit catalogues. Drugs that have been approved by the 
European regulatory authority EMA are being launched simultaneously in 
European markets. In addition, medical products and technologies are being 
launched nearly at the same time in European markets. 
The EU-project “EUnetHTA – European Network for Health Technology 
Assessments” is concerned with the development and implementation of 
structures and networks for transnational HTA-cooperation. This project 
was funded by the EU from 2006 to 2008 and was continued without public 
funding throughout 2009. From 2010 until 2012, it is again being funded by 
the EU in the form of a Joint Action. 
The LBI-HTA was co-initiator and has been a leading partner of EUnetHTA 
for several years. The LBI-HTA manages Work Package 7 in close coopera-
tion with the French HAS/Haute Authorité de Santé. Work Package 7 is 
concerned with rapid exchange of information on the assessment of new 
technologies after their approval, but prior to their introduction on the mar-
ket. 
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2 Research 
2.1 Projects and Scientific Support of 
Decision-Making 
Strengthening the Evidence Base for a Learning Health System: In-
spirations from Good Practice for Capacity Building in Health Ser-
vices Research and Public Health Research 
Project leader: Claudia Wild 
Project team: Nikolaus Patera 
Duration: 06/2010 – 02/2011 
Background: WHO published its “World Report on Knowledge for Better 
Health – Strengthening Health Systems” in 2004. The EU’s 6th Framework 
Programme for Research analysed the status quo of public health research. 
The current 7th Programme looks at health services research. Always of cen-
tral importance is the question of how theoretical knowledge can be trans-
lated into practical action. 
Aims and research objectives: To stimulate the debate on enablers of high-
quality health services research and public health research, LBI-HTA initi-
ated a report on the organisation and governance of health services research 
and public health research. A successful system (organisation and govern-
ance) of health services research and public health research enables institu-
tional and human resources capacity building, which are foundations of 
high-quality research. The report starts off by touching upon some of the 
conceptual and theoretical issues relating to knowledge gaps in health sys-
tems, capacity building for research and the interface of research and policy. 
Then concrete examples for good practice from the Netherlands, Denmark, 
Norway and the UK are presented to gain ideas and draw inspiration. 
Methods: The starting points for (unsystematic) literature searches were re-
ports on the topic funded by international organisations (WHO, EU). Using 
a snowballing system, the literature sources of interest listed in these reports 
were further explored. To explore organisational examples of good practice, 
information about institutions relevant for health services research and pub-
lic health research in a range of countries was gathered on the Internet. 
Building upon the information available on the websites, institutions were 
chosen to conduct in-depth expert interviews on. Senior experts in these or-
ganisations were asked to participate in person in a semi-structured interview 
via telephone. Eventually, 13 such interviews lasting between 45 and 90 min-
utes were conducted with experts from organisations showing elements of 
good practice in the Netherlands, Denmark, Norway and the UK. 
Results: Not least due to a long-standing and well-funded research tradition 
and a culture open to evidence-based policy debate, model organisations in 
the field of health services research and public health research are particu-
larly found in the Netherlands and in the UK. 
Transparent processes of prioritising research questions, of communicating 
research results and of evaluating research and its implementation are neces-
sary to establish a research system positively impacting the practice of politi-
cal decision-making. Trust between decision-makers and researchers, charac-
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terised by intensive interaction along the entire research process, is a prereq-
uisite for the ultimate user relevance of research. Scientific competence in the 
narrow sense on the part of the research organisation needs to be coupled 
with the ability to actively communicate with decision-makers and with net-
work-building skills. This can be enhanced by organisational structures in 
research commissioning, academia and independent research organisations. 
In addition to political will, organisational leadership and sustainable fund-
ing commitments, capacity building requires time for a culture of problem 
solving in mutual respect to develop between decision-makers and research-
ers. A perspective on research that takes organisational and systemic perspec-
tives on board, that understands the production of evidence as a shared proc-
ess and that is sensitive to context offers the most promising way forward. 
Publication: HTA-Project Report No. 48: Strengthening the knowledge base 
for a better health system. Inspirations from good practice for capacity build-
ing in health services research and public health research - 
http://eprints.hta.lbg.ac.at/908 
Systematic Review of the Efficacy and Safety of Treatments for Vari-
cose Veins of the Lower Extremity 
Project leader: Marisa Warmuth  
Project team: Marisa Warmuth, Ines Schumacher, Bettina Maringer  
Duration: 05/2011 – 08/2011 
 
Background: Varicose veins of the lower extremity are a sign of varicose in-
sufficiency and are the most common venous disease in Germany. According 
to the study “Bonner Venenstudie” (2000-2002, N=3.072), only about 14% of 
men and 6% of women aged between 18 and 79 years do not have any sign of 
venous insufficiency, including telangiectasias, reticular veins, varicose 
veins, oedema, skin changes or ulceration. Besides hereditary risk factors, 
advancing age, female sex, pregnancy, obesity as well as physical inactivity 
promote the development of varicose veins. Treatment options encompass 
conservative measures, conventional surgery (ligation with or without strip-
ping) and minimally-invasive interventions (sclerotherapy, lasertherapy, ra-
diofrequency ablation).  
Aims of project: The project aims at assessing the current evidence regarding 
efficacy and safety of different treatment options for varicose veins, including 
conventional surgery (ligation with or without stripping, phlebectomy), 
minimally-invasive interventions (sclerotherapy, endovenous laser therapy 
and endovenous radiofrequency ablation), as well as conservative measures 
(compression therapy). In addition, it aims at comparing the various treat-
ment options and at defining a boundary between indicated sur-
gery/interventions and surgery/interventions for cosmetic reasons.  
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Research objectives: 
1. What is the current evidence regarding the efficacy and safety of 
therapeutic options (including conventional surgery, phlebectomy, 
minimally-invasive treatment options and conservative measures) 
for varicose veins of the lower extremity?  
2. Which are the indications and contraindications for conventional 
surgery, minimally-invasive interventions, as well as compression 
therapy?  
3. Is there an algorithm to treat patients according to severity of the 
disease?  
4. Is there a definition of a boundary between indicated sur-
gery/interventions and surgery/interventions for cosmetic reasons? 
If not, is it possible to define such a boundary?  
Methods: 
 Contacting of HTA institutions / social insurance companies that 
are currently working on the same topic (identification through the 
EUnetHTA Planned and Ongoing Projects (POP)-database) for pos-
sible collaborations  
 Developing the project protocol based on the following systematic 
review: Australian Safety and Efficacy Register of New Interven-
tional Procedures – Surgical. Systematic Review: Treatments for 
varicose veins. ASERNIP-S Report No. 69; October 2008. 
http://www.surgeons.org/media/19316/Varicose_Veins(SR).pdf [Ac-
cessed 6 May 2011]  
 Systematic literature search in various databases (Pubmed, The 
Cochrane Library, Medline via Ovid, NHS-EED-DARE-HTA) and 
on web sites  
 Unsystematic hand search 
Publication: HTA Project Report No 51 -http://eprints.hta.lbg.ac.at/930  
Quality of Care in Oncology and Its Measurement 
Project leader: Claudia Wild 
Project author: Nikolaus Patera 
Duration: 02/2011 – 10/2011 
Background: The spectrum of conditions classified under the term “cancer” 
poses particular challenges for quality measurement. Multimodal treatment 
combinations (surgery, chemo-, hormone-, immune-, radiation therapy) for 
this increasingly chronic illness frequently alternate between in- and outpa-
tient settings. Multiple actors in the healthcare sector need to be monitored 
over what are often extended periods of time in order to measure quality. 
Aims and research questions: To provide an information input on the ongoing 
development of the Austrian National Cancer Plan, this report addressed the 
following study questions: 
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 What are properties of high-quality oncological care?  
 Which quality indicators for oncological care are available interna-
tionally? Which initiatives work on these?  
 What are important elements in indicator development for on-
cological care?  
 What are the practical challenges of implementing systems of qual-
ity measurement in cancer care? 
Methods: A systematic literature search in databases – reviewed independ-
ently by two researchers – was followed by an unsystematic hand search via 
Google and on relevant homepages. To identify additional literature, experts 
in the field were contacted. 
Results: The report focuses on ongoing activities and initiatives in the area of 
quality measurement in cancer care. 22 of these from seven countries are pre-
sented in some detail. In addition, 17 complete indicator sets are included in 
the appendix. Further development efforts are particularly needed for quality 
indicators that compare subgroups, indicators for less-frequent cancers, indi-
cators that take psychosocial elements into account or address quality of life 
and incorporate patients’ perspectives. The same is true for end-of-life care 
quality indicators. 
Conclusion: Apart from the obviously required know-how for indicator devel-
opment and the necessary establishment of an efficient electronic data collec-
tion infrastructure, knowledge about and experience with the development of 
clinical guidelines and patient pathways are crucial for establishing a quality 
system for cancer care. Data analysis and feedback skills are required. In or-
der to actually improve quality at the point of patient care delivery, a sense of 
ownership for the quality improvement process needs to be fostered amongst 
stakeholders. 
Publication: HTA-Project Report No. 049: [Quality of care in oncology and its 
measurement] - http://eprints.hta.lbg.ac.at/934 
Reorientation of the Austrian Parent-Child Preventive Care Pro-
gramme 
Background of the project first year (see parts I-IV): The mother-child-pass ex-
amination programme was launched in Austria in 1974. Since then, the spec-
trum of examinations has been steadily extended and the number of exami-
nations has continuously increased. However, to date, neither the programme 
itself nor recently emerging needs have been systematically evaluated. An 
evaluation of the Austrian mother-child-pass examination programme pri-
marily aims at analysing the specific needs of the target population in terms 
of width and depth of both existing services and new / different services re-
quired as well as challenging the evidence-base of existing examinations in a 
second step.  
The mother-child-pass examination programme is a classical (epidemiologi-
cal) screening programme amongst healthy individuals. However, WHO cri-
teria for screening should be applied. Currently, the mother-child-pass ex-
amination programme comprises examinations of both the pregnant mother 
from the point of pregnancy detection until delivery and the child from birth 
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up to the 62nd month of life. The current mother-child-pass is predomi-
nantly “medicine-focussed” and more or less excludes diagnostic procedures 
/ care provided by other health professionals than doctors, such as midwives, 
nurses, physiotherapists, psychologists, social workers, amongst others. 
However, this contrasts with more recent regional / national and interna-
tional screening models primarily targeting risk populations (e.g., socially 
deprived women and children, women and children with a migration back-
ground, etc.) that have special needs related to mother-child health care ser-
vices.  
Programme services have mainly been publicly financed by several public 
payers. Additionally, different incentive systems have been introduced to in-
crease the uptake of services. In order to establish a system of care that meets 
current needs, adequate financing structures are required. 
Aim of the overall project: The aim is the development of a decision support 
document for the re-orientation of the mother-child prevention programme 
in Austria. It aims at easing the re-organisation process for stakeholders in 
order to adjust the prevention programme to the actual needs of the respec-
tive target population.  
Reorientation of the Austrian Parent-Child Preventive Care Pro-
gramme - Part I: Epidemiology – Frequencies of Risk Factors and 
Diseases in Pregnancy and Early Childhood. 
Project leader: Brigitte Piso  
Project team: Marisa Warmuth, Philipp Mad, Brigitte Piso, Claudia Wild 
Additional project contribution: Tarquin Mittermayr, Ines  
Schumacher, Stefan Mathis-Edenhofer 
Duration: 04/2010 – 03/2011 
Objectives part 1: Epidemiology and assessment of risk factors, as well as dis-
eases. A synthesis and analysis of epidemiological data concerning existing 
risk factors and diseases in defined target groups aims at highlighting the 
spectrum of risk factors and diseases, including their frequency. It should 
provide the basis for the assessment of services required.  
Research questions part 1: Epidemiology and assessment of risk factors, as well 
as diseases 
1. Which risk factors/diseases occur in the respective target group, how 
often do they occur?  
2. Which risk factors occur in the respective target group at the indi-
vidual level (age, sex, hereditary factors and life style factors) and at 
the environmental level (social networks, working and living condi-
tions, socioeconomic, cultural, and environmental factors)? How of-
ten do they occur and in which severity?  
3. Are there differences in risk factors / diseases in the respective target 
group depending on sociodemographic parameters, such as age, 
educational level, socioeconomic status, ethnic background, etc.? 
Method part I:  
 Systematic literature search in the following databases: CRD-
INAHTA, Embase, Ovid Medline, PsycINFO, PSYNDEX, The 
Cochrane Library, Web of Science and MedPilot  
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 Hand search in databases, selected medical journals, committees of 
professional societies, HTA institutions  
 Synthesis of statistical data from Austria (Statistik Austria, birth 
registry, health reports) concerning diseases / risk factors / risky be-
haviour  
 Comparison of assessed statistical data with the current mother-
child-pass examination programme concerning examinations / miss-
ing examinations / lacking data  
 Workshop with national experts 
Publications:  
Part I: HTA Project Report 045a - http://eprints.hta.lbg.ac.at/912/ 
Reorientation of the Austrian Parent-Child Preventive Care Pro-
gramme - Part II: International Policies, Concepts and Screening 
Strategies Focusing on “Normal” and “High-Risk” Development 
Processes during Pregnancy and Early Childhood until School Entry  
 
Project leader: Brigitte Piso  
Project team: Roman Winkler 
Additional project contribution: Imke Schall, Tarquin Mittermayr  
Duration: 04/2010 – 03/2011 
Objectives part II: The second part will cover a comparative analysis focussing 
on similar screening-instruments in the international context – on the one 
hand, this shall involve experiences relating to particular services provided 
for risk populations, as well as, on the other hand, other innovative services 
aspects for mother-child health.  
Methods part II: Internet search on public sector information; systematic lit-
erature search and hand search in databases; questionnaire; comparative 
analysis of international screening-instruments and services; workshop with 
national experts. 
Research questions part II: 
1. Which medical and psycho-social parameters are examined along-
side mother-child examinations? Which time intervals are usually 
provided for mother-child examinations?  
2. Which professional groups (e.g., medical doctors, nurses, midwives, 
etc.) are involved and at which stages of the overall examination 
process?  
3. Are there any country-specific mother-child health care aspects that 
inform about the service range, as well as the service depth (i.e., ser-
vices for special groups such as women experiencing domestic vio-
lence, etc.)? 
Publication: 
Part II: HTA-Project Report No 45b - http://eprints.hta.lbg.ac.at/913/ 
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Reorientation of the Austrian Parent-Child Preventive Care Pro-
gramme- Part III: Financing Structures of Services and Public Trans-
fers for Parents and Young Children 
Project leader: Brigitte Piso  
Project team: Ingrid Zechmeister-Koss, Tina Liobl 
Additional project contribution: Tarquin Mittermayr 
Duration: 04/2010 – 03/2011 
Objectives part III: Part three will describe the financing structures (payers, 
monetary flows, transfer of services), the inherent incentives, as well as the 
costs and expenditure of current services (mother-child-pass examinations 
and other preventive measures for pregnant women, newborns and children). 
Research questions part III:  
1. What are the financing structures (payers, monetary flows, and ser-
vice recipients) of the current maternity and child care programmes, 
what is the legal basis and how are they integrated in the overall 
health and social system?  
2. What are the incentives and what is the impact from the incentives 
(e.g., uptake of services) of the different systems historically? Are 
there international best practice models with respect to financing 
and incentive systems?  
3. What are the financing structures (payers, monetary flows, service 
recipients) of preventive services (in-kind or monetary) for pregnant 
women, newborns and children “beyond” the current maternity and 
child care programme?  
4. What are the costs for single services and what have been the total 
public (and private) expenditures for maternity and child care pro-
grammes? 
Methods part III: Evaluation of public documents on financing structures and 
legal frameworks; interviews with payer representatives to gain additional in-
formation; analysis of costs and expenditure based on administrative data 
(e.g., from social security funds and hospitals, ministry) and on secondary 
literature. 
Publication: 
Part III: HTA Project Report 045c- http://eprints.hta.lbg.ac.at/914/ 
Reorientation of the Austrian Parent-Child Preventive Care Programme 
Part IV: Synthesis of Parts I-III, Recommendations 
Project leader: Brigitte Piso  
Project team: Brigitte Piso, Roman Winkler, Marisa Warmuth  
Duration: 04/2010 – 03/2011 
Contracting authority: BMG (Austrian Ministry of Health) 
Objectives part IV: Based on the results of parts 1-3, we aim to assess the ac-
tual needs in terms of services required. 
Research questions part IV: 
 Which of the identified risks are adequately detected by the current 
maternity and child care programme?  
 Are these risks also internationally considered in routine prevention 
(or prevention policy)?  
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 Which other, seemingly relevant health risks are alternatively/ addi-
tionally considered internationally in maternity / child prevention 
programmes and for which target group?  
 Is there any experience regarding how these risks can be detected 
and which consequences of risk-population-prevention (strategy) 
could be observed?  
 Which role does the financing of preventive measures (included / 
not included in the current maternity / child programme) take? 
Methods part IV: 
 Synthesis of results of parts 1-3; comparison of contents / financial 
structure of the current maternity and child care programme with 
identified risks and international approaches 
Publication:  
Part IV: HTA Project Report 045d - http://eprints.hta.lbg.ac.at/915/ 
Reorientation of the Austrian Parent-Child Preventive Care Pro-
gramme - Part V: Preterm Birth 
Project leader: Brigitte Piso 
Project team: Brigitte Piso, Ines Schumacher 
Additional project contribution: Veronika Häussler, Tarquin Mittermayr 
Duration: 03/2011 – 12/2011 
Background part V: In the preceding reports of the parent-child screening / 
prevention project, we repeatedly identified preterm birth as a highly rele-
vant health issue. In part I we pointed out differences in the definition of pre-
term births and subsequent differences in figures (depending on the defini-
tion and / or data source). We also stated that Austria is a “front-runner” in 
the prevalence of preterm births in Europe (with 11% according to gesta-
tional age). We identified preterm deliveries, including causes and conse-
quences, as an independent category of most common and potentially lethal 
health threats when ranking health risks for frequency of occurrence and se-
verity of health consequences in part IV. Referring to the four major risk 
groups for an overall increased risk of disease, we also identified and named 
“pregnant women expecting multiples or preterm infants” as an individual 
risk group. 
Aims of part V: 
1. to illustrate the preterm birth rate in Austria in the European con-
text in-depth to see if it is possible to find any trends or relations  
2. to give an overview on primary, secondary preventive as well as 
screening measures for decreasing the preterm birth rate  
3. if possible, highlight pilot programmes which are successful in re-
ducing preterm birth rates 
Research objectives part V:  
Ad 1: 
 Is it possible to find trends with respect to preterm birth rates and 
associated factors, like mother’s age or the multiples birth rate when 
comparing Austrian and European data, and can relations between 
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these factors and the preterm birth rate be derived from this com-
parison?  
 How does the preterm birth rate in Austria present itself compared 
to other European countries, based on different data sources? 
Ad 2: 
 Are primary preventive measures to decrease the preterm birth risk 
for all pregnant women in comparison with routine preventive care 
effective in decreasing the preterm birth rate, in reducing infant and 
maternal mortality and infant morbidity, and safe (intervention-
based complications / burden for mother or child)?  
 Are screening measures for identifying pregnant women with an in-
creased risk for preterm birth in comparison with routine preven-
tive care without screening effective in decreasing the preterm birth 
rate, in reducing infant and maternal mortality and infant morbid-
ity, and safe (intervention-based complications / burden for mother 
or child)?  
 Are secondary preventive measures to decrease the preterm births 
for pregnant women with an increased risk for preterm birth in 
comparison with routine preventive care effective in decreasing the 
preterm birth rate, in reducing infant and maternal mortality and 
infant morbidity, and safe (intervention-based complications / bur-
den for mother or child)? 
Ad 3: 
 Are there pilot programmes in Austria or Europe for decreasing the 
preterm birth rate / the risk of preterm birth?  
 Which measures had been taken to successfully decrease the pre-
term birth rate? 
Methods: 
1. Extraction of data from different data sources about preterm birth 
and associated factors in Europe  
2. Systematic search for literature / additional hand search for system-
atic reviews / meta-analyses for a systematic review  
3. Hand search including contacting national / international experts 
Publication:  
Part V: HTA-Project Report No. 50 - http://eprints.hta.lbg.ac.at/939 
Reorientation of the Austrian Parent-Child Preventive Care Pro-
gramme - Part VI: Health Visiting Services in the International Con-
text and Implementation Options for Austria 
Project leader: Brigitte Piso 
Project team: Roman Winkler, Judit Erdös, Bernd Wimmer 
Duration: 05/2011 – 03/2012 
Background: The Ludwig Boltzmann Institute for Health Technology As-
sessment recently published four reports on behalf of the Austrian Ministry 
of Health dealing with parent-child screening / prevention issues. With re-
gards to international parent-child health strategies, two reports (II and IV) 
focused on diverse screening services for pregnant women, parents and chil-
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dren in selected (European) countries. Concerning the involved health pro-
fessionals, it turned out that health visitors represent integral parts of the 
screening and prevention programmes in several countries. In Austria, preg-
nant women, parents and children have to actively consult the health services 
providers (mainly doctors and / or medical specialists). This policy contrasts 
with many other countries where specially trained health experts (e.g., mid-
wives, public health nurses, etc.) provide services in the living environment 
of the target groups. However, these services are also partly offered in public 
education institutions (e.g., nursery schools, kindergarten, schools, etc.) or 
they are essential elements of parent-child screening / prevention pro-
grammes offered by institutions of public health systems. This follow-up pro-
ject will deal in depth with country-specific health visiting programmes and 
it will flesh out potential implementation options for Austria.  
Aims of project:  
Part VI/1: Training contents, job requirements and competence areas of 
health visitors in selected countries. Part 1 provides a country overview re-
garding diverse training programmes and job profiles for health visiting ser-
vices and informs about related competences and areas of health visitors.  
Part VI/2: International evaluation experiences (incl. staff requirements and 
acceptance rates) and evidence profiles concerning health visiting services 
that have a particular focus on socio-medical risk groups. Part 2 summarises 
country experiences and evidence profiles for health visiting services. This 
part particularly focuses on pregnant women, parents and children exposed 
to potential socio-medical risk factors.  
Part VI/3: Status-quo of health visiting services for pregnant women, parents 
and children in Austria. Part 3 pursues the goal of reporting on already exist-
ing health visiting services in Austria and of investigating evaluation experi-
ences (e.g., acceptance rates).  
Part VI/4: Implementation options for health visiting services in Austria. 
Part 4 concludes on the preceding chapters and aims at discussing potential 
health visiting models for pregnant women, parents and children in Austria.  
Research questions:  
Part VI/1: Which training contents are offered in international programmes 
preparing for the job as a health visitor? Which competence areas do health 
visitors in other countries have?  
Part VI/2: What is the evidence for the efficacy of health visiting services for 
pregnant women, parents and children with and without socio-medical risk 
profiles (e.g., substance abuse, teenage pregnancy, poverty, etc.)? Which 
evaluations (e.g., in terms of acceptance rates) have been undertaken so far? 
To what extent do target groups (particularly those with socio-medical risk 
factors) make use of health visiting services? Which staff requirements (in 
terms of number of health staff needed) are internationally recommended?  
Part VI/3: Which health visiting services for pregnant women, parents and 
children are already offered in Austria? How can these services be accessed 
by the target groups? Which groups of health professionals have so far of-
fered visiting services to pregnant women, parents and children? How many 
health visitors are there in Austria, respectively, in selected Austrian regions? 
How many pregnant women, parents and children have benefited so far from 
health visiting services in Austria, respectively, in selected Austrian regions?  
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Part VI/4: Which implementation options for health visiting services can be 
developed for the Austrian context? 
Methods: 
Part VI/1 and VI/3: Hand search, Internet search on public sector informa-
tion, expert interviews, etc. 
Part VI/2: Hand search, Internet search, systematic literature search on evi-
dence profiles concerning health visiting services in parent-child screening / 
prevention programmes  
Part VI/4: Discussion of results and conclusions on Parts VI/1 – VI/3 
Reorientation of the Austrian Parent-Child Preventive Care Pro-
gramme - Part VII: Options for an Electronic Implementation 
Project leader: Brigitte Piso 
Project team: Stefan Mathis-Edenhofer 
Additional project contribution: Florian Schramm, Tarquin Mittermayr 
Duration: 05/2011 – 03/2012 
Background: The last year of the parent-child-prevention programme “new” 
project aimed at giving basic support to a decision on a new prevention strat-
egy for parents during pregnancy and infants. Part I of the project summa-
rised epidemiological data on specific risks, part II described international 
screening policies and part III provided an overview of the financial structure 
of the current parent-child-prevention program. Part IV – which comprises a 
comprehensive summary of the results – highlighted the critical importance 
of electronically realised systems for data collection and data analysis in the 
context of a newly structured parent-child-prevention program. 
Austria is currently organising and performing activities related to the par-
ent-child-prevention programme (“Mutter-Kind-Pass”) in a paper-based 
manner. The aim of this new project part VII is to learn from main national 
and international parent-child initiatives by analysing the information and 
communication processes of these initiatives. In the main, the project aims at 
examining suitable possibilities to implement activities related to a “new” 
parent-child-prevention programme in the context of eHealth and particu-
larly in the context of ELGA. 
Aims of the project: 
 To identify information processing and communication elements of 
a “new” parent-child-prevention programme by an analysis based on 
the preceding project parts (part I-IV) and by additionally analysing 
a selection of national and international parent-child-prevention 
initiatives.  
 To test (on a conceptual level) the feasibility of implementing in-
formation processing and communication elements within ELGA or 
within alternative forms.  
 To demonstrate possibilities and obstacles.  
Research questions: 
1. What are the activities and elements of a proposed “new parent-
child-prevention program” that are based on of the previous project 
parts?  
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2. Which are national and international parent-child-prevention ini-
tiatives?  
3. Which information processes and communication components exist 
within the main parent-child-prevention initiatives?  
4. What can ELGA offer to implement information processes and 
communication components?  
5. Which parent-child-prevention activities could be implemented 
through ELGA and which alternatives should be considered?  
6. What are the challenges of implementing components of a “new 
parent-child-prevention program”  
Methods Ad 1 and 2: 
 Identification of activities based on the previous project parts that 
can be considered for a “new parent-child-prevention program”  
 Systematic literature search on electronically implemented national 
and international parent-child-prevention initiatives  
 Identification of information and communication components of a 
“new parent-child-prevention program” 
Methods Ad 3: Description of information and communication components of 
a “new parent-child-prevention program”, use cases, activities 
Methods Ad 4: Description of ELGA framework conditions 
Methods Ad 5 and 6: Description of perspectives on implementation possibili-
ties, their limitations, preconditions and alternatives 
Reorientation of the Austrian Parent-Child Preventive Care Pro-
gramme - Part VIII: Budget Impact Analysis 
Project leader: Ingrid Zechmeister-Koss 
Project team: Ingrid Zechmeister-Koss, Stefan Fischer, Judit Erdös 
Additional project contribution: Tarquin Mittermayr 
Duration: 06/2011 – 03/2012 
Background: In part III of the project, we identified which payers are cur-
rently financing the parent-child programmes and what the public expendi-
ture is. Implementing an alternative programme has financial consequences 
for the different payers involved. Additionally, the programme will have 
wider economic consequences.  
Aims of project: Part VIII aims at analysing the financial consequences 
(budget impact) of implementing an alternative parent-child preventive care 
programme. We will specifically address the budget impact of health visiting 
services (part VI) and electronic implementation (part VII). Re-distribution 
potentials and cost-offsets will be taken into account.  
Research questions:  
 Which scenarios of preventive care programmes and related mix of 
services (type of service, frequency, profession involved) are to be 
expected in comparison to the current service provision?  
 Which costs will occur for which payers within a 5-year time hori-
zon?  
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 Which changes in health status are to be expected and what will be 
the economic impact and the impact for public budgets? 
Methods:  
 Designing a framework (model) for the analysis based on parts I to 
VII  
 Evaluating costs based on Austrian data on services, tariffs, income 
data, international experiences and assumptions (in cases where no 
data are available)  
 Identifying resources that are required for the preventive care 
scenarios (e.g., services of different health care professionals, 
infrastructure, implementation)  
 Identifying quantities of resource consumption (e.g., estimated 
hours of care)  
 Valuing the resources (e.g., price per hour of midwife care)  
 Calculating the total costs (in the form of cost ranges) of sce-
narios addressed  
 Addressing uncertainty of parameters via sensitivity analyses  
Evaluation Study at the University Department of Child and Adoles-
cent Psychiatry at the Christian Doppler Clinic, Salzburg, Austria 
Project lead and co-operation: Roman Winkler (overall project) and Ingrid Zech-
meister-Koss (economic evaluation) in co-operation with the University Department 
of Child and Adolescent Psychiatry at the Christian Doppler Clinic, Salzburg, Aus-
tria (Leonhard Thun-Hohenstein and Corinna T. Fritz) and Christoph Obermair 
(IT) 
Duration: 01/2010 – 12/2012 
Background: In Austria, evaluation research in the context of child and ado-
lescent psychiatry is still in the early stages. This co-operation project is per-
ceived as a scientific contribution to the improvement of quality evaluations 
within the context of child and adolescent psychiatry.  
Aims and research questions: Since April 2011, the current evaluation study has 
been collecting data based on the outcome parameters identified in previous 
research (LBI-HTA project reports 27 and 28). This includes outcomes that 
relate to psychiatric, psychotherapeutic, psychological and socio-pedagogical 
treatments and services. 
The following research questions guide the evaluation study:  
- To what extent do children and adolescents at the Salzburg Clinic (inpa-
tient and outpatient) experience “changes” in the course of time?  
- What is the amount of resources before and during the stay in the clinic? 
How do resources relate to the service needs of the patients ant to the costs 
and effects of the treatment?  
Methods: Primary data collection of the University Department of Child and 
Adolescent Psychiatry at the Christian Doppler Clinic, Salzburg, Austria; 
quantitative instruments (e.g., concerning treatment effects, patients’ satis-
faction with treatments and services, life quality, etc.) and qualitative in-
struments  of empirical social research (e.g., interviews with patients, par-
ents). The data evaluation is undertaken by means of SPSS.   
The data collection will be examined across four points of measurement in 
order to detect “clinical changes” in the course of time. Patients and their 
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family members are asked at   
T1: Start of the treatment  
T2: Discharge   
T3: 6 weeks after discharge  
T4: 1.5 years after discharge 
The economic evaluation will involve the collection of data, such as duration 
and frequency of therapy units, and will consider services that are provided 
by various health professionals at the clinic. Moreover, the project collects 
survey data about all services used by patients before and after their stay in 
the clinic.  
Results: Interim results are expected to be published in summer 2012. 
Appraisal of the Quality and Accuracy of Written Consumer Health 
Information for Patients with Chronic Myeloid Leukaemia on 
Treatment Regimens with Dasatinib, Nilotinib or Imatinib 
Project leader: Claudia Wild 
Project team: Katharina Hintringer, Jone Gerdvilate 
Duration: 04/2011 – 02/2012 
Background: With the approval of nilotinib and dasatinib for the first-line 
treatment of patients with Philadelphia chromosome-positive chronic mye-
loid leukaemia in the chronic phase (Ph+CML-CP) in 2010, there are now 
three different chemotherapeutic agents available for the treatment of this 
indication. The drugs nilotinib and dasatinib have been directly compared to 
the current standard of care, imatinib within phase III pivotal trials. At a 
median follow-up of 18 months, the estimated overall survival rate in the 
dasatinib group was 96%, compared to 97.9% in the imatinib group 
(DASISION trial), 98.5% in the nilotinib group 300mg twice daily, 99.3% in 
the nilotinib group 400mg twice daily, and 96.9% in the imatinib group 
(ENESTnd trial). 
Based on the interim efficacy and safety data of these two trials, the question 
arises as to which treatment option should be chosen for which patient and 
where the patients get the information from. While physicians are still the 
most important source of health-related information for patients, studies 
show that 80-90% of patients search for additional information about their 
health issues within the Internet and traditional media by themselves. With-
out access to high-quality information about their disease and different 
treatment options, patients will not be able to make informed choices regard-
ing their therapy. Thus, this project aims to appraise the quality and accu-
racy of written consumer health information on imatinib, dastatinib and 
nilotinib for the treatment of Ph+CML-CP. 
Aims: 
1. Identification and collection of written (Internet- and paper-based) 
consumer health information on imatinib, dasatinib and nilotinib 
for the treatment of CML  
2. To identify checklists and criteria to appraise the structural quality 
and content of patient information  
3. Appraisal of the quality of the identified patient information  
4. Appraisal of the accuracy of the proposed information on efficacy 
and safety 
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Research questions: 
 What are the sources to identify and comprehensively collect writ-
ten consumer health information about imatinib, dasatinib and 
nilotinib?  
 What is the most suitable search algorithm within search engines to 
find the information?  
 Which parameters constitute the structural quality of consumer 
health information?  
 Which criteria are relevant to appraise the accuracy of consumer 
health information?  
 Which standardised checklists are available to appraise the quality 
and accuracy of written consumer health information?  
 Do the identified patient information documents provide accurate 
information about the specific drugs and treatment options?  
 To what extent does the patient information meet structural quality 
requirements? 
Methods: 
 Identification of consumer health information on imatinib, 
dasatinib and nilotinib:  
 Search within search engines (www.google.com, 
www.yahoo.com, www.bing.com) with the terms (imatinib, 
glivec, nilotinib, tasigna, dasatinib, sprycel). A separate search 
will be conducted for each term and the first 60 links will be 
checked whether they meet the inclusion criteria (patient in-
formation about one of the three drugs for the therapy of 
CML).  
 Directly contact national and European umbrella organisations 
of patient organisations, medical societies related to leukaemia, 
health ministries and the Marketing Authorisation Holder of 
the drugs and ask them to provide their patient information 
material related to the treatment of CML with these or one of 
these three drugs. 
 Appraisal of the quality and accuracy of the information with a suit-
able quality appraisal instrument (e.g., DISCERN, IPDAS Checklist 
…) and by applying criteria for evidence-based patient information. 
Occupational Therapy in Austria 
Project leader: Brigitte Piso 
Project team: Ines Schumacher 
Duration: 05/2011 – 2012 
Background: There are different definitions describing “occupational ther-
apy”. According to the World Federation of Occupational Therapists, occu-
pational therapy “is a profession concerned with promoting health and well-
being through occupation. The primary goal is to enable people to participate 
in the activities of everyday life”. These outcomes will be achieved by “ena-
bling people to do things that will enhance their ability to participate or by 
modifying the environment to better support participation” (WFOT, 2004). 
Occupational therapy is primarily used in paediatrics, psychiatry, neurology, 
geriatrics and orthopaedics. Services are provided in inpatient care (e.g., in 
programme line 1 
Annual Report 
2011 
38 LBI-HTA | 2012 
psychiatric, rehabilitation or support of mentally or physically disabled peo-
ple). For outpatient care, occupation therapy must be prescribed by a general 
practitioner. Most of the service is provided by selected occupational thera-
pists (“Wahlergotherapeuten”). Treatment costs are reimbursed by the social 
insurance on a pro-rata basis. 
Aims of project: To give an overview of the current conditions of occupational 
therapy in Austria (education, type and number of services provided, number 
of therapists). 
Research objectives:  
 How is the education study for occupational therapists organised?  
 Which target groups receive (what kind of) service?  
 How many occupational therapists are working in Austria and to 
what extent are services provided (including trends)?  
 How can physiotherapy services be differentiated? 
Methods: Unsystematic literature research, interviews, data from occupational 
therapists and social insurance. 
Exercise Therapy (Krankengymnastik / Heilgymnastik) in Physical 
Medicine 
Project leader: Marisa Warmuth 
Project team: Ines Schumacher, Marisa Warmuth  
Duration: 10/2011 – 12/2011 
Suggested by: HVB 
Background: Exercise therapy (Krankengymnastik / Heilgymnastik) is a do-
main of physical medicine and sometimes is still referred to by the out-dated 
term “Mechanotherapy”. It is most often used for the treatment of diseases 
and conditions that primarily affect the musculoskeletal system, such as os-
teoarthritis, rheumatoid arthritis, neurological diseases, etc. Exercise therapy 
(Krankengymnastik / Heilgymnastik) may be conducted as single therapy or 
in groups of patients. Its intended purpose is to practice patterns of move-
ment for therapeutic purposes. 
Aim of project: The project aims at assessing evidence concerning the efficacy 
and its measurement, as well as the indications of exercise therapy (Kran-
kengymnastik / Heilgymnastik). 
 
Research objectives: 
1. What does exercise therapy (Krankengymnastik / Heilgymnastik) 
consist of? 
2. What are common indications for exercise therapy (Krankengymnas-
tik / Heilgymnastik)? 
3. What is the evidence for the efficacy of exercise therapy (Kranken-
gymnastik / Heilgymnastik)? 
4. How is the efficacy of exercise therapy (Krankengymnastik / Heil-
gymnastik) measured?  
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Methods: 
 Systematic literature search in various databases (Pubmed, The 
Cochrane Library, Medline via Ovid, NHS-EED-DARE-HTA, 
PEDRO) and on web sites  
 Unsystematic hand search 
Training Therapy in Physical Medicine 
Project leader: Marisa Warmuth 
Project team: Nikolaus Patera, Marisa Warmuth  
Duration: 10/2011 – 12/2011 
Background: Training therapy is a domain of physical medicine and – like 
other forms of exercise therapy – aims at facilitating physical activity via in-
structed physical exercise based on the principles of exercise physiology. 
Training therapy takes the forms of exercise using an ergometer (bicycle or 
treadmill) or circle training, and is indicated in various conditions, such as 
musculoskeletal diseases, cardiovascular and pulmonary diseases and neuro-
logical diseases. Training therapy is divided into endurance training and 
strength training; however, usually a combination of these two forms of 
training is employed. Following an initial phase of instruction, training ther-
apy is usually conducted in groups and aims at motivating patients to life-
long training. 
Aim of project: The project aims at assessing the evidence concerning the effi-
cacy of training therapy and its measurement via an overview of systematic 
reviews. 
Research objectives: 
1. What does training therapy consist of?  
2. What are common indications for training therapy? 
3. What is the evidence for the efficacy of training therapy? 
4. How is the efficacy of training therapy measured? 
Methods: 
 Systematic literature search in databases (Pubmed, The Cochrane 
Library, Medline via Ovid, NHS-EED-DARE-HTA, PEDRO) and 
on web sites  
 Unsystematic hand search 
Evaluation of Individual Medical Services (MELs) 
Project leader: Claudia Wild 
Project team: all LBI researchers 
Duration: 01/2011 – 04/2011 
Suggested by: BMG (Austrian Ministry of Health) 
Background: Each year, the Austrian Ministry of Health receives suggestions 
for the reimbursement of numerous new medical interventions. The aim of 
this project is to evaluate the efficacy and safety of interventions suggested 
for inclusion in the MEL (German for “individual medical services”) cata-
logue. Themes (interventions) are prioritised by the Ministry of Health and 
contracted out to the LBI-HTA.  
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Method: The assessments are based on systematic reviews of each interven-
tion and a summary of the scientific evidence according to the GRADE 
scheme. Since 2009, the LBI-HTA has cooperated with its German counter-
parts “NUB Neue Untersuchungs- und Behandlungsmethoden” (“New Ex-
amination and Treatment Methods”), which also appraises relevant new 
medical interventions using the same method. 
For the first time, international cooperation with other EUnetHTA partners 
(Agency for Quality and Accreditation in Health, Department for Develop-
ment, Research and Health Technology, Zagreb, Croatia; Radiation Oncol-
ogy, Istituto Oncologico Veneto-IRCCS-Padova; Heppatobiliary Surgery and 
Liver Transplantation Unit, University of Padova, Italy; Agenas, Agenzia 
nazionale per i servizi sanitari regionali, Rome, Italy) took place in the con-
text of the EU project “EUnetHTA Joint Action 2010-2012” (see Chapter 1.5) 
for the 2011 MEL cycle. Within this framework, bilingual (G/E) MEL As-
sessments were jointly carried out. 
Results: In 2011, a total of five decision support documents as well as one up-
date were written:  
MEL Interventions 2011: 
 Vascular-Endothelial-Growth-Factor-Inhibitors (anti-VEGF) in 
the Management of Diabetic Macular Oedema.  
DSD 43: http://eprints.hta.lbg.ac.at/917 
 Percutaneous left atrial appendage closure for the prevention of 
thromboembolic events in patients with atrial fibrillation 
 DSD 44: http://eprints.hta.lbg.ac.at/918 
 Renal denervation in patients with essential hypertonia 
DSD 45: http://eprints.hta.lbg.ac.at/8919 
 Mechanical percutaneous transluminal cerebral clot retrieval de-
vices in acute ischemic stroke: Systematic Review on efficacy 
and safety  
DSD 46: http://eprints.hta.lbg.ac.at/920 
 Selective internal radiotherapy using yttrium-90 microspheres 
for primary and secondary liver malignancies. 
DSD 47: http://eprints.hta.lbg.ac.at/922 
1 MEL intervention update 2011: 
 Percutaneous aortic valve replacement (with a side note to hy-
brid operating rooms)  
DSD 18 / Update 2011: http://eprints.hta.lbg.ac.at/923 
Methods: The assessments are based on a systematic review conducted for 
each intervention, and summaries of the evidence based on the GRADE 
framework.  
HTA in Hospitals: Organisation and Coordination of a Decision-
Makers Network  
Programme leader: Claudia Wild 
The informal “HTA in Hospitals” network consists of a group of about 20 
high-ranking decision-makers (medical directors and quality managers) from 
almost exclusively Austrian hospital cooperation. The network meets twice a 
int. cooperation with: 
MDS / GER 
further cooperation 
among EUnetHTA 
partners planned 
MELs 2011 
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year (June and October) in order to obtain informative HTA input into four 
key topics, to discuss them and to exchange ideas on regulation and reim-
bursement issues. 
The task of the LBI-HTA is to coordinate the meetings, to request and col-
lect current topics and to prepare the presentations. The format of the meet-
ings is that each topic will be presented from the HTA perspective and by an 
invited clinical expert, which subsequently leads into a structured discussion.  
HTA in Hospitals, 05/04/2011: 
Topics and presentations: 
 The German Aortic Valve Registry: Univ.-Prof. Dr. Friedrich W. 
Mohr (DGTHG, Leipzig) 
 Position paper on transcatheter-supported aortic valve interven-
tions: Univ.-Prof. Dr. Wilfried Wisser (ÖKG + ÖGTHC, AKH-
Vienna) 
 Aspects of patient selection for TAVI: Dr. Franz Harnoncourt 
(KH-ELISABETHINEN, Linz)  
5 short presentations on 2011 MELs:  
 Vascular-Endothelial-Growth-Factor-Inhibitors (anti-VEGF) in the 
Management of Diabetic Macular Oedema.: Dr. Ingrid Zechmeis-
ter-Koss (LBI-HTA) 
 Percutaneous left atrial appendage closure for the prevention of 
thromboembolic events in patients with atrial fibrillation: Dr. Ma-
risa Warmuth (LBI-HTA) 
 Renal denervation in patients with essential hypertonia: Dr. DI 
Stefan Mathis-Edenhofer (LBI-HTA) 
 Mechanical percutaneous transluminal cerebral clot retrieval de-
vices in acute ischemic stroke: Systematic Review on efficacy and 
safety: Dr. DI Stefan Mathis-Edenhofer (LBI-HTA) 
 SIRT / SSelective internal radiotherapy using yttrium-90 micro-
spheres for primary and secondary liver malignancies.: Dr. Anna 
Nachnebel (LBI-HTA)  
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HTA in Hospitals, 27/09/2011: 
Focus: Oncology – national and local activities 
Lecturers: 
 Univ. Prof. Dr. Richard Greil (Oncology Working Group in the 
Austrian Federal Ministry of Health): National Cancer Plan: Work-
ing Groups/Coordination Activities 
 Mag. Nikolaus Patera (LBI-HTA): Clinical Outcomes Measure-
ment and Quality of Treatment in Oncology 
 DI Günther Zauner (Drahtwarenhandlung, Vienna): GAP-DRG 
Database Evaluations on Cancers 
 Dr. Karin Eglau (KRAGES, Burgenland): Onko-Dekurs Informati-
on System of the KRAGES  
 OA Dr. Jörn Decker (GESPAG, Upper Austria): Onco-Database of 
the GESPAG  
 Univ. Prof. Dr. Richard Greil (SALK, Salzburg): Coordination Ac-
tivities in Salzburg 
Methods: Presentations, Discussions 
The intention of programme line 3 “Public Understanding and Research 
Transfer” is to build up – through presentations, seminars, trainings, a 
monthly newsletter, a user-friendly webpage and search support – a critical 
mass of patients, journalists, representatives of the health administration, 
academia, etc., that questions the information presented and asks for sound 
evidence before decision-making. 
Project leaders: Claudia Wild, Gerda Hinterreiter 
The seminar series “Decision Support in Health Care” addresses the health 
administration, journalists, health care academics and the interested general 
public. Two to six presentations are offered per year, with free admission. 
Duration: about two hours, including scientific discussions. In 2011, three 
seminars were organised and attended by 15 to 25 persons. 
Seminar Series: Decision Support in Health Care 
07/07/2011 | 15:00 | Gesellschaft der Ärtze 
Lecturer: Prof. DDr. Heiner Raspe, Dr. Christiane Druml 
Two lectures followed by discussion on the topic „Gerechtigkeit im Gesund-
heitswesen: Ethische Kosten-Nutzen Überlegungen und Umsetzung in der 
Praxis“  
Workshop „Lernendes Gesundheitssystem“ - Produzieren wir brauchba-
res Wissen? Wie kommt es in der Politik an? 
11/05/2011 | 13:30 | Spitalgasse 2-4, Hof 2 (Alte Kapelle), Altes AKH, Cam-
pus 
Meeting „Eltern-Kind Vorsorge - Herausforderungen und Perspektiven“ 
06/12/2011 | 08:30-16:00 | Festsaal des BMG Tagung in Cooperation with 
BMG /Austrian Ministry of Health) 
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Figure 2.1-1: “Parent-Child-Care New” programme 
For the employees of the LBI-HTA, methodological training sessions are 
given by experts two to three times a year. External colleagues can also be in-
vited to attend.  
Möglichkeiten und Bereiche zur Einreichung von Projektanträgen im 7. 
Rahmenprogramm der EU, Bereich Gesundheit und HTA  
05/05/2011 | 9:00-11:00 |  
Lecturer: Dr. Astrid Höbertz and Dr. Ylva Huber / FFG - Austrian Research 
Promotion Agency, Division for European and International Programmes  
ELGA / Elektronische Gesundheitsakte – ein Überblick  
13/05/2011 | 14:00-16:00 | 
Lecturer: Dr. Susanne Herbek, Geschäftführerin ELGA GmbH 
Das Gesundheitswesen in Wien  
17/05/2011 | 15:30-17:00 |  
Lecturer: Dr. Otto Rafetseder, MPH, Magistrat Wien, MA 24 Gesundheit & 
Soziales 
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Informationsverarbeitung, Visualisierung und Analyse durch bibliometri-
sche Verfahren  
12/07/2011 | 15:00-16:00 | 
Lecturer: Dr. Dirk Holste, AIT/Austrian Institute of Technology.  
EUnetHTA POP database Version 1.0 – Präsentation und Training  
08/11/2011 | 13:00-14:30 |  
Lecturer: Mag. Gerda Hinterreiter, LBI-HTA 
Gesundheitsökonomische Forschung an der JKU mit österreichischen 
Individualdaten  
22/11/2011 | 15:00-16:30 |  
Lecturer: Prof. Dr. Gerald J. Pruckner, Volkswirtschaftslehre, Johannes 
Kepler Universität, Linz 
Zulassung von Medizinprodukten in Europa 
13/12/2011 | 15:00-16:30 | 
Lecturer: Dr. Wolfgang Ecker, BMG 
The aim of the HTA Newsletter, which is regularly published online, is to 
summarise international HTA results in the form of short, easy-to-read arti-
cles. For each Newsletter, four articles about relevant technolo-
gies/interventions are selected. Often, but not always, topics which at least 
two different HTA institutions have worked on and published independently 
are chosen. An editorial, often penned by an invited expert, deals with inter-
disciplinary topics: methodological issues, health policy issues, etc. The 
HTA-Newsletter (which was published by the Austrian Academy of Sciences 
between 2001 and 2006 and has since been published by the LBI-HTA) is 
published 10 times per year; September 2011 saw the publication of its 100th 
edition.  
The HTA Newsletter, which is sent to approximately 900 people in Austria 
and Germany via the HTA mail distributor, has continued to receive positive 
feedback.  
The HTA-Newsletter download page of the LBI-HTA 
(http://hta.lbg.ac.at/de/newsletter.php?iMenuID=63) received between 812 
(July) and 1,602 (November) hits per month in 2011, with a total number of 
14,110 hits.  
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Figure 2.1-2: Download HTA-Newsletter 2009, 2010 & 2011 
Project leaders: Claudia Wild, Gerda Hinterreiter  
Duration: 10 x p. a. 
The work of the LBI-HTA or its employees was featured in 35 articles, press 
releases, radio and TV interviews in 2011. These were: 
Wer zahlt, schafft an 
Date: 27/01/2011 
Medium: ÄrzteWoche 
Article 
Buchrezension: Zahlenspiele in der Medizin 
Date: 01/2011 
Medium: Therapieinfo (WGKK), Jg. 23 01/2011, S. 12 
Book review 
Stöger und Hauptverband arbeiten an Spitalsreform 
Date: 06/02/2011 
Medium: APA 
Press report 
Spitalsreform: Experten hoffen auf Druck der leeren Kassen 
Date: 06/02/2011 
Medium: Tiroler Tageszeitung 
Article 
Stöger und Hauptverband arbeiten an Spitalsreform 
Date: 06/02/2011 
Medium: Kleine Zeitung 
Article 
Stöger und Hauptverband arbeiten an Spitalsreform 
Date: 06/02/2011 
Medium: PR-inside 
Article 
 
press review 2011:  
35 articles 
/contributions  
Download HTA-Newsletter 2009, 2010, 2011
http://hta.lbg.ac.at/de/newsletter_download.php
Jun
Dec
Jan
Oct
Aug
Jul
Mar
Feb Apr
Nov
SeptMay
0
200
400
600
800
1.000
1.200
1.400
1.600
1.800
Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec
Monate
C
ou
nt
Download Newsletter 2009 Download Newsletter 2010 Download Newsletter 2011
insg. 13.907 insg. 13.937 insg. 14.110
Annual Report 
2011 
46 LBI-HTA | 2012 
Stöger und Hauptverband arbeiten an Spitalsreform 
Date: 06/02/2011 
Medium: Der Standard 
Article 
Stöger bringt Spitalsreform auf den Weg 
Date: 06/02/2011 
Medium: Heute 
Article 
Stöger und Hauptverband arbeiten an Spitalsreform 
Date: 06/02/2011 
Medium: Life Radio 
Article 
Stöger und Hauptverband arbeiten an Spitalsreform 
Date: 06/02/2011 
Medium: Salzburger Nachrichten 
Article 
Stöger und Hauptverband arbeiten an Spitalsreform 
Date: 07/02/2011 
Medium: GMX bzw. Standard.at 
Article 
Spitalsreform: Hauptverband will in Stögers Gremien mitarbeiten 
Date: 07/02/2011 
Medium: OÖ Nachrichten 
Article 
Das Ausverhandeln hinter geschlossenen Türen hat damit ein Ende 
Date: 02/2011 
Medium: doktorinWien 
Article 
Patientengespräch = Spitzenmedizin 
Date: 02/2011 
Medium: Jatros Kardiologie & Gefäßmedizin, Feb. 2011, Nr. 1 
Article 
Wirkungsforschung für die Gesprächsmedizin 
Date: 15/03/2011 
Medium: Ärztemagazin 05/2011 
Article 
Wie viele Daten braucht der Arzt? 
Date: 06/04/2011 
Medium: Medical Tribune 43. Jg. Nr. 14 
Article (print, online) 
LBI-HTA: Neue Berichte 
Date: 04/2011 
Medium: Qualitas 01/2011 Jg.10 
Announcement/News 
 
Research 
LBI-HTA | 2012 47 
Eltern-Kind-Vorsorge neu 
Date: 02/05/2011 
Medium: Bundesministerium für Gesundheit/Website 
Webtext 
Health Technology Assessment: Was HTA wirklich kann 
Date: 10/05/2011 
Medium: Österreichische Ärztezeitung 
Article (front text) 
Claudia Wild, Director of LBI Health Technology Assessment 
Date: 06/06/2011 
Medium: Ludwig Botzmann Gesellschaft, Folder “LBG 2010” 
Interview  
Mutterseelen, allein 
Date: 14/06/2011 
Medium: Das österreichische Gesundheitswesen/ÖKZ 
Article 
HPV-Impfprogramm zeigt erste Erfolge 
Date: 21/06/2011 
Medium: Der Standard online 
Article 
HPV-Impfung und Gebärmutterhalskrebs – Fakten & Übertreibungen 
Date: 01/07/2011 
Medium: medizin-transparent.at 
Article 
Teure Spielerei oder medizinische Hoffnungsträger? Biologika auf dem 
Prüfstand 
Date: 05/07/2011 
Medium: Ö1 Dimensionen - Die Welt der Wissenschaft 
Radio programme 
Spital 2011: Einfluss der Krankenhausgröße auf Qualität und Effizienz 
Date: 15/07/2011 
Medium: Klinik 03/2011, p. 29 
Article 
Meilenstein für die Eltern-Kind-Vorsorge aus dem LBI für HTA 
Date: 26/07/2011 
Medium: Politische Kindermedizin Newsletter 9/2011, p. 5 
Article 
MEGRA-Konferenz: „Efficacy versus Effectiveness – die Zukunft der 
Nutzenbewertung von Arzneimitteln“ 
Date: 29/08/2011 
Medium: Periskop 48/11, p. 36 
Article 
Zulassungsbehörden bewerten Arzneien unterschiedlich 
Date: 21/09/2011 
Medium: Wiener Zeitung, p. 17 
Article 
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Was wirklich wirkt 
Date: 09/2011 
Medium: Clinicum 9/11, p. 34-35 
Article 
Die Suche nach dem Kosten-Nutzen-Risikoprofil 
Date: 04/10/2011 
Medium: derStandard.at 
Article 
Die Diskussion wird nicht geführt 
Date: 19/10/2011 
Medium: ÖKZ 52. Jg. (2011), 10 
Interview 
Menschen, über die man spricht: Claudia Wild 
Date: 21/10/2011 
Medium: medianet 
Article 
Arzneimittelzulassungen: Unterschiede zwischen EU und USA 
Date: 11/11/2011 
Medium: doktor in wien, 11-2011, p. 20 
Article 
Moderne Eltern-Kind-Vorsorge - Querdenken und neue Perspektiven fin-
den! 
Date: 21/12/2011 
Medium: “Medical Tribune” Nr. 51-52/2011 
Article 
1 Media Highlight in 2011 was:  
 TV Review on ATV life : ExpertInnenstatement zur HPV-Impfung, 
14.04.2011 (Brigitte Piso) 
 
The LBI-HTA press review 2011 is also available at: 
http://hta.lbg.ac.at/de/content.php?iMenuID=60 
Project leader /Press contact: Gerda Hinterreiter  
The LBI-HTA website – http://hta.lbg.ac.at – contains updated announce-
ments or presentations of publications and reports, research projects, events, 
press reviews, team profiles and other current news concerning the LBI-
HTA.  
According to the website statistics, the Institute’s homepage and webpages 
had 1,029,518 hits in 2011. A monthly comparison shows that the fewest hits 
were received in December (77,151), and that May saw the highest number 
of hits (109,580). 
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Figure 2.1-3: Website hits 2009, 2010 & 2011 
 
Figure 2.1-4: Website visits 2011 
Project leader/Webmaster: Gerda Hinterreiter  
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Outpatient Cardiac Rehabilitation. Part IV: Options for a Prospective 
Study 
Project leader: Brigitte Piso 
Project team: Brigitte Piso, Heinz Tüchler 
Duration: 04/2010 – 07/2011 
 
Background: After the completion of the retrospective cohort study in June 
2010 and the prolongation of the contracts between the Association of Aus-
trian Health Insurance Providers (HVB) and outpatient rehabilitation cen-
tres of the working group on outpatient cardiac prevention and rehabilitation 
(AGAKAR), which is linked to an “evaluation” of phase III rehabilitation 
until 2014, HVB suggested that the LBI-HTA should prepare options for a 
prospective study to assess the effectiveness of phase III cardiac rehabilita-
tion.  
Aim of project: The aim of this project part was to inform decision-makers in 
the health care systems about options for a prospective cardiac rehabilitation 
study (focussing on the comparison of phase III vs. no further rehabilitation), 
including their respective (dis)advantages, the different underlying research 
questions that can be answered, as well as suggestions for operationalisation. 
Methods: Numerous meetings with representatives of the HVB, pension and 
health insurances and the AGAKAR, e.g., to determine study aims and to 
discuss the organisational framework. Manual search for cardiac rehabilita-
tion studies, their outcome parameters and assessment instruments to sup-
plement literature of previous project parts. Sample size calculation for all 
potential primary endpoints based on data from the previous retrospective 
study and literature. Suggestion of a study design that is feasible under the 
given terms. 
Publication: Outpatient cardiac rehabilitation part IV: Options for a prospec-
tive study. Decision Support Document No. 48 - 
http://eprints.hta.lbg.ac.at/928 
Outpatient Cardiac Rehabilitation. Part V: Study Protocol “Multi-
Centre Prospective Controlled Observational Study with Two Parallel 
Groups on Outpatient Cardiac Phase III Rehabilitation” 
Project leader: Brigitte Piso 
Project team: Brigitte Piso, Heinz Tüchler 
Duration: 09/2011 – 02/2012 
 
Background: Six- to twelve-month outpatient cardiac phase III rehabilitation 
following phase II is currently provided at several sites in Austria. Based on 
international studies, the effectiveness of cardiac rehabilitation seems to be 
proven in general. However, there is a lack of studies on the long-term effec-
tiveness of (short) phase II programmes or on optional subsequent phase III 
compared to no further rehabilitative measures. There is at least limited evi-
dence that effects (positive impact on cardiovascular risk factors) that have 
been achieved in phase II are not sustainable. Phase III therefore aims at pre-
venting aggravation of risk factors or even at a further improvement. The 
planned study is based upon extensive preliminary work of the LBI-HTA 
(outpatient cardiac rehabilitation parts I to IV): After the completion of the 
retrospective cohort study in June 2010 and the prolongation of the contracts 
programme line 4 
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between the Association of Austrian Health Insurance Providers (HVB) and 
outpatient rehabilitation centres of the working group on outpatient cardiac 
prevention and rehabilitation (AGAKAR), which is linked to an “evaluation” 
of phase III rehabilitation until 2014, LBI-HTA prepared options for a pro-
spective study to assess the effectiveness of phase III cardiac rehabilitation 
until July 2011 (see Decision Support Document Nr. 48).  
Now the study protocol is to be developed based on the chosen study option 
(prospective, non-randomised, controlled observational study with two com-
parison groups (with /without phase III)). 
Research question of the study: Will patients with disadvantageous risk profile 
(at least three out of six risk factor categories of the rehabilitation target area) 
who attend a phase III programme after phase II show a health benefit (op-
erationalised by fewer risk factors of the target area on average) compared to 
the control group without phase III 18 months after end of phase II? 
Methods: The study protocol will be developed based on detailed preliminary 
work and further project group meetings with representatives of the HVB, 
pension insurance (PVA) and AGAKAR, as well as the medical directors of 
the involved inpatient cardiac rehabilitation centres.  
Use of Routine Data and Further Relevant Secondary Data in the 
HTA Chapter in the Austrian HTA Manual) 
Project leader: Ingrid Zechmeister-Koss 
Project team: Ingrid Zechmeister-Koss 
Duration: 05/2011 – 08/2011 
 
Publication: The chapter will be published in the next version of the Austrian 
Methods Manual (2012). Upon request, Dr. Ingrid Zechmeister-Koss will 
provide more detailed information. 
Background: In addition to data from clinical studies on the efficacy of a 
technology, Health Technology Assessment  
often requires routine data (e.g., administrative data) and data derived from 
other sources than classical research (e.g., registries). Identification and use 
of such data has not been addressed in HTA manuals so far.  
Aims of project: This project aims at writing a chapter in the Austrian HTA 
manual on the use of routine databases and further secondary data sources 
(e.g., registries) in the context of HTA. The chapter will cover methodologi-
cal issues and additionally present an overview of Austrian data sources, in-
cluding information on their access and their characteristics.  
Research questions: 
 When, during the HTA process, are secondary data useful and when 
are they required?  
 How can these data be classified?  
 Which type of routine data and further useful secondary data exist 
in Austria?  
 What kind of methodological standards exist for using those data?  
 Methods: Literature search for definitions, classification and meth-
odological standards for using secondary data within HTA, search 
for Austrian data sources based on “snowball sampling” (addressing 
representatives from administration, researchers…), guest author-
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ship for the description of selected data sources (“keepers” of the 
data), external review by a methodological specialist and by “keep-
ers” of the data 
Horizon Scanning in Oncology - Part II: From Pilot to Routine 
Project leader: Anna Nachtnebel 
Project cooperation: Katharina Hintringer 
Duration: regularly since October 2008 
 
Background: The establishment of a Horizon Scanning System for anticancer 
drugs is an important tool to prepare Austrian hospitals for new / emerging 
medicines. The first part of our project “Horizon Scanning in Oncology”, 
which was carried out between July 2007 and May 2008, focused on the de-
velopment of a concept for a Horizon Scanning System in oncology and the 
testing of two important steps (i.e., “identification” and “prioritisation”) in 
the context of a short pilot. On the whole, our initial experiences with the 
Horizon Scanning System from the feasibility study were acceptable, but sev-
eral changes, especially regarding the collection of data on anticancer drugs 
and the priority-setting process, were proposed by the involved experts. 
Aims and research objectives: Based on these findings, the second part of the 
project aims to implement the proposed concept. Therefore, the next steps 
will be to work out an optimised final concept with various stakeholders (e.g., 
hospital administrators, clinical experts and drug commissions), taking into 
consideration the results of the feasibility study. In addition, the Horizon 
Scanning System should be made standard practice at the LBI-HTA to regu-
larly provide Austrian hospitals (hospital management and drug commis-
sions) with information about new / emerging anticancer drugs to support 
their financial drug budget planning and rational decision-making. As an in-
put for the international HTA community, the Ludwig Boltzmann Institute 
for HTA joined the “International Information Network on New and Chang-
ing Health Technologies” (EuroScan) in November 2008. 
Method: Development of an optimised and final concept of “Horizon Scan-
ning in Oncology” (Part I: http://eprints.hta.lbg.ac.at/798/) with involvement 
of several decision-makers (e.g., drug commissions), followed by its imple-
mentation in standard practice.  
Members of the interdisciplinary oncology team of experts are:  
 Dr. Anna BUCSICS, Hauptverband der Österr. Sozialversicherung-
sträger, Abteilung Evidence-Based Economic Healthcare, Vienna; 
 Dr. Michael POBER, KH St. Pölten, Hämato-Onkologie, Lower 
Austria Landeskliniken Holding; 
 Dr. Johannes ANDEL, LKH Steyr, Onkologie und Public Health, 
GESPAG, Upper Austria; 
 Mag. Andreas SEIRINGER, LKH Vöcklabruck, Stellv. Leiter 
Krankenhausapotheke – Pharmazeut, GESPAG, Upper Austria; 
 Prim. Dr. Peter KRIPPL, LKH Fürstenfeld, Hämatologie und On-
kologie, KAGES, Styria; 
 Dr. Wolfgang WILLENBACHER, LKH Innsbruck Universitäts-
klinik, Hämato-Onkologie, TILAK, Tyrol; 
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 Mag. Sigrid KIENDLER, LKH Innsbruck, Stellv. Leiterin Kran-
kenhausapotheke – Pharmazeutin, TILAK, Tyrol; 
 Dr. Clemens LEITGEB, Wilhelminenspital, Onkologie und Häma-
tologie, KAV, Vienna  
Results: As they are promptly available and written in English, the “Horizon 
Scanning in Oncology” documents have drawn major attention and impor-
tance beyond the Austrian borders. Due to the apparent EU-wide redun-
dancy and the increasing demand for assessments of oncologica, a two-day 
“Workshop on Onco Drugs” took place at the end of September/beginning of 
October 2011 at the LBI-HTA, where 20 persons from 12 European HTA in-
stitutes met for the first time to work out mutual ways and possibilities for 
future rapid cooperation in the oncology assessment field. This workshop 
was initiated and hosted by the LBI-HTA as the lead partner of the WP 7B of 
the EUnetHTA Joint Action. One of the first results of this successful meet-
ing is the composition of a Horizon Scanning in Oncology Assessment, to-
gether with a partner institute at the University Clinic in Bremen (beginning 
of January 2011). 
Publications: Since Autumn 2009, a total of 20 Horizon Scanning in Oncology 
Decision Support Documents and 3 Updates were compiled, 7 DSDs and 3 
Updates alone in 2011:  
 Ipilimumab for pretreated patients with advanced/metastatic mela-
noma. DSD: Horizon Scanning in Oncology 14.  
http://eprints.hta.lbg.ac.at/905/ 
 Nilotinib (Tasigna®) for the 1st-line treatment of Philadelphia 
chromosome positive chronic myeloid leukemia in the chronic 
phase. DSD: Horizon Scanning in Oncology 15.  
http://eprints.hta.lbg.ac.at/906/ 
 Cabazitaxel (Jevtana®) for the second-line therapy of patients with 
hormone-refractory metastatic prostate cancer. DSD: Horizon 
Scanning in Oncology 16. http://eprints.hta.lbg.ac.at/911/ 
 Dasatinib (Sprycel®) for the 1st-line treatment of Philadelphia 
chromosome positive chronic myeloid leukaemia in the chronic 
phase DSD: Horizon Scanning in Oncology Nr. 17. 
http://eprints.hta.lbg.ac.at/910/ 
 Eribulin (Halaven®) als “third or late-line” Monotherapie bei fort-
geschrittenem/metastasiertem Brustkrebs. DSD: Horizon Scanning 
in Oncology 18. http://eprints.hta.lbg.ac.at/927/ 
 S-1 (Teysuno) in chemotherapy-naive patients with advanced 
NSCLC. DSD: Horizon Scanning in Oncology 19.  
http://eprints.hta.lbg.ac.at/931/ 
 Abiraterone acetate (ZytigaTM) as 2nd-line therapy for the treatment 
of metastatic castration-resident prostate cancer after docetaxel ther-
apy . DSD: Horizon Scanning in Oncology 20. 
+ 3 Updates:  
 Gefitinib (Iressa®) for the 1st-line treatment of non-small cell lung 
cancer – 1st Update 2011. DSD: Horizon Scanning in Oncology 06 
/Update 2011. http://eprints.hta.lbg.ac.at/935 
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 Panitumumab (Vectibix®) as 1st line combination therapy for the 
treatment of WT KRAS metastatic colorectal cancer - 1st Update 
2011. DSD: Horizon Scanning in Oncology 11 / Update 2011. 
http://eprints.hta.lbg.ac.at/936/ 
 Rituximab (Rituxan®/MabThera®) for the first- and second-line 
treatment of chronic lymphocytic leukaemia - 1st Update 2011. 
DSD: Horizon Scanning in Oncology 04 / Update 2011 
http://eprints.hta.lbg.ac.at/937/ 
IFEDH - Innovative Framework for Evidence-based Decision Mak-
ing in Health Care 
Project leader: Ingrid Zechmeister-Koss 
Project team: Philipp Radlberger 
Duration: 10/2010 – 03/2011 
Background: The extraordinary high amount of 20-25 billion Euros of annual 
turnover in the Austrian health system has increasingly raised the questions 
of cost-effectiveness and evidence-based decision-making in health care. 
Health technology assessment is already intensively dealing with these is-
sues, especially on the level of single interventions. Still, due to lack of data, 
assessments often include modelling or simulation techniques in order to 
analyse long-term effects. This, in turn, requires increasing cooperation of 
experts from different fields of science, such as HTA, statistics, data man-
agement, modelling & simulation, as well as visualisation. A common under-
standing on contents, methodology and terminology needs to be developed. 
In Austria, such a common understanding has hardly been elaborated in a 
systematic way up to now.  
Aims of project: It is the main aim of the IFEDH project to support evidence-
based decision-making in health care by a service tool which helps profit 
from existing potentials in HTA, modelling, simulation, statistics and data 
analysis. Therefore, common standards will be defined in order to facilitate 
cooperation and interdisciplinary work. Based on three practical examples, 
the tool will be tested regarding his applicability.  
LBI-HTA took the leading role in Work Package 1 (WP1), as well as the exe-
cution of WP1.2 and WP2.1. Both WPs will address state-of-the-art standards 
in HTA. AP1.2 is focussing on quality standards of the discipline in general, 
and on the evaluation of vaccination programmes in particular. The aim is to 
publish an English review. AP2.1 describes the terminology of simulation 
and modelling in the specific context of HTA. The aim is to create a glossary 
in English and German, considering the most relevant international sources. 
Research objectives AP1.2:  
What are general principles of standardised work in HTA? 
Which standards exist to examine data validity in primary studies? 
Which standards exist to examine data validity in systematic reviews? 
Which standards exist to examine economic studies? 
Which standards in HTA manuals exist to examine modelling? 
Which standards explicitly refer to evaluating vaccination programmes? 
Which are the limitations that HTA is subject to, regardless of quality stan-
dards? 
Research 
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Research objectives AP2.1: What are the German and English linguistic stan-
dards according to HTA criteria in matters of definitions and terminology in 
modelling and simulation? 
Methods AP1.2 & AP2.1: Hand search based on methodological manuals of 
leading international institutions, as well as hand search in other relevant lit-
erature. AP1.2: Description of sources, list of standards and critical synthesis 
of results in the English language; AP2.1: Table of identified terms in the 
form of a glossary. 
Project meetings were held, within the framework of the Austrian “Network-
ing project” IFEDH, on 27/04/2011, 28/06/2011, 29/08/2011 and 19/10/2011.  
Publication: WP 1.2 “Standardised working in HTA” (HTA Project Report No. 
44a) - http://eprints.hta.lbg.ac.at/932 
EUnetHTA Joint Action 2010-2012 
Project leader: Claudia Wild 
Project team: Claudia Wild, Gerda Hinterreiter, Marisa Warmuth, Stefan Mathis, 
Anna Nachtnebel 
Duration: 2006-2008; 2009; 2010-2012  
Background: In the course of termination of the EU project EUnetHTA 2006-
2008, the partner organisations aimed to develop a strategic concept in order 
to ensure the continuation of EUnetHTA in the interim period of 2009. 
Overall, a group of 25 partner organisations, so-called “founding partners”, 
from 13 EU member states (+ Norway and Switzerland) actively worked on 
the sustainability of this project. The LBI-HTA was a “founding partner” of 
the EUnetHTA Collaboration in 2009. Following the interim period, this co-
operative scheme has now, thanks to long-term funding from the EU, devel-
oped into the “Joint Action 2010-2012”.  
Aims and methods: In this Joint Action, the LBI-HTA is leading Work Pack-
age 7B, with the aim of reducing overlaps in EU-wide HTA work. From 2010 
to 2012, WP 7/B will develop a web-based database containing all ongoing 
and planned assessments of the EUnetHTA Joint Action partner organisa-
tions in order to avoid overlaps in HTA work across the EU. A web-based da-
tabase of all Planned and Ongoing Projects (POP database) is to be made 
available to all EUnetHTA partner organisations.  
Results: Since January 2010, the LBI-HTA has been collecting planned and 
ongoing projects every three months. These projects are sorted according to 
topic and are made available to partners. The web-based POP database is cur-
rently being developed in cooperation with the Belgian HTA Institute KCE. 
It was completed in Summer 2011 and subsequently made available to all 
contributing (content-providing) EUnetHTA partners.  
There has been further cooperation with other EUnetHTA partner organisa-
tions, such as during the LBI-HTA “Horizon Scanning in Oncology” pro-
ject. Further cooperation, for example in the 2011 MEL assessments, is plan-
ned (in progress).   
Publications: Available at EUnetHTA website http://www.eunethta.eu 
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Newsletter March 2011; 95:4. 
Hinterreiter, G. (2011): Pharmakogenetische Tests in der Krebstherapie. 
HTA-Newsletter February 2011; 94:2. 
Hintringer, K. (2011): Individuelle Gesundheitsleistungen – Was nutzt den 
PatientInnen? HTA Newsletter November 2011 (Nr. 101):3. 
Hintringer, K. (2011): PET bei Gehirntumoren. HTA Newsletter August 
2011 (Nr. 99):3-4. 
Hintringer, K. (2011): Horizon Scanning in der Onkologie. Ipilimumab & 
Nilotinib. HTA-Newsletter February 2011 (Nr. 94):4. 
Nachtnebel, A. (2011): Surrogatendpunkte in der Onkologie. HTA-
Newsletter April 2011. Nr. 96.  
Nachtnebel, A. (2011): SIRT bei Lebermalignomen. HTA-Newsletter June 
2011. Nr. 98.  
Nachtnebel, A. (2011): S-1 (TeysunoTM) bei Lungenkrebs. HTA-
Newsletter October 2011. Nr. 100.  
Patera, N. (2011): Qualitätsindikatoren in der Onkologie am Beispiel Brust-
krebs. HTA-Newsletter April 2011, Nr. 96. 
Patera, N. (2011): Versorgungsqualität in der Onkologie. HTA-Newsletter 
September 2011, Nr. 100. 
4 posters 
28 HTA-Newsletter 
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Piso, B. (2011): Health Literacy – Gesundheitskompetenz, HTA-Newsletter. 
August 2011, Nr. 99. 
Piso, B. (2011): Eltern-Kind-Vorsorge neu Teil IV: Synthese der Teile I-III, 
Handlungsempfehlungen, HTA-Newsletter. May 2011, Nr. 97. 
Piso, B. (2011): Nichtkommerzielle klinische Forschung in Deutschland Sta-
tus quo und Optimierungsvorschläge, HTA-Newsletter. March 2011, Nr. 95. 
Radlberger, P. (2011): Radiotherapie bei Prostatakrebs. HTA-Newsletter 
March 2011; 95:2. 
Radlberger, P. (2011): Alkoholsucht – Klinische Leitlinien in GB. HTA-
Newsletter November 2011; 102:4. 
Schumacher, I. (2011): PET bei Ovarial- und rezidivierendem Kolorektal-
karzinom. HTA-Newsletter October 2011, 101:2. 
Schumacher, I. (2011): Impact von HTA auf das Gesundheitswesen in Ös-
terreich. HTA-Newsletter February 2011, 94:3. 
Warmuth, M. (2011): Therapieoptionen bei Krampfadern. HTA-Newsletter 
August 2011: 2. 
Warmuth, M. (2011): Perkutaner Vorhofohr-Verschluss bei Vorhofflim-
mern. HTA-Newsletter June 2011: 2. 
Warmuth, M. (2011): Eltern-Kind-Vorsorge neu. Teil I: Epidemiologie. 
HTA-Newsletter May 2011: 2.  
Warmuth, M. (2011): Interstitielle Brachytherapie bei Prostatakrebs. HTA-
Newsletter April 2011: 2. 
Winkler, R. (2011). Bariatrische Chirurgie bei schwerer Adipositas, HTA-
Newsletter March 2011: 3.  
Winkler, R. (2011). Eltern-Kind-Vorsorge neu: Teil II: Eltern-Kind-
Screenings im internationalen Vergleich, HTA-Newsletter May 2011: 1.  
Winkler, R. (2011). Ambulante Versorgung bei COPD, HTA-Newsletter Oc-
tober 2011: 4. 
Zechmeister-Koss, I. (2011): Katarakt-Operationen. Indikationsstellung ist 
entscheidend. HTA Newsletter October 2011: 2-3. 
Zechmeister-Koss, I. (2011): Anti-VEGF bei diabetischem Makulaödem. 
HTA Newsletter June 2011: 2. 
Zechmeister-Koss, I. (2011): Ist-Erhebung der Finanzierungsstrukturen 
von Eltern-Kind-Leistungen in Österreich. HTA Newsletter May 2011: 3 
2.3 Participation in Scientific Meetings 
January:  
 Discussion Forum “How can the quality of treatment in oncology 
be sustainably improved?” Berlin/Germany, 19/01/2011, (Anna 
Nachtnebel, Katharina Hintringer). 
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February: 
 Children’s and Young People’s Health in Austria, Presse-Club-
Concordia, Vienna, 03/02/2011 (Roman Winkler). 
March: 
 12th Annual Conference of the DNEbM (German Network for 
Evidence-based Medicine), “EbM and Individualised Medicine”, 
Berlin/Germany, 24.-26/03/2011 (Ingrid Zechmeister-Koss, Marisa 
Warmuth, Anna Nachtnebel). 
May: 
 Federal Health Conference, “Health Goals”, Federal Ministry of 
Health, Vienna, 16/05/2011 (Claudia Wild, Brigitte Piso). 
June: 
 116th Public Health Special Training Course, Klagenfurt, 16.-
17/6/2011 (Ingrid Zechmeister-Koss). 
 Conference on Reproductive Medicine – Quo Vadis? What does 
society want? Vienna, 20.-21/6/2011 (Ingrid Zechmeister-Koss, 
Claudia Wild). 
 HTAi Rio de Janeiro, Brazil, 26.-29/06/2011 (Marisa Warmuth). 
August: 
 Green Summer Academy, “Good Life for Everyone”, Goldegg, 25.-
27/08/2011 (Claudia Wild). 
September: 
 Symposium of the German Network for Evidence-based Medi-
cine, “Evaluations of Complex Situations”, Wittenberg, 09/09/2011 
(Roman Winkler). 
 14th Scientific Conference of the Austrian Society for Public 
Health, “Money and Health. The Transition from Healthcare Sys-
tem to Healthcare Economy”, Linz, 29-30/9/2011 (Ingrid Zechmeis-
ter-Koss, Brigitte Piso, Roman Winkler). 
 Congress of the German Society for Social Medicine and Preven-
tion (DGSMP) and the German Society for Medical Sociology 
(DGMS) in Cooperation with the Health Insurance Medical Ser-
vice (MDK), “Socially and Sustainably Forming Prevention”, Bre-
men/Germany, 21.-23/09/2011 (Claudia Wild, Anna Nachtnebel). 
October: 
 Congress of the European Forum for Evidence-Based Prevention, 
“Cancer Prevention”, Krems, 12.-13/10/2011 (Ingrid Zechmeister-
Koss). 
 IIR Congress, Quality Benchmarking in the Hospital, Vienna, 10.-
12/10/2011 (Claudia Wild). 
 8th Discussion Forum 2011 of the SEG 6 “Drug Supply” and the 
Field of Evidence-Based Medicine of the Medical Advisory Service 
of the Germany Social Health Insurances (MDS): “Early Drug 
Benefit Assessment in the Scope of the Law on Realignment of 
the Pharmaceutical Market in Germany (AMNOG)”, Dort-
mund/Germany, 20/10/2011 (Anna Nachtnebel). 
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November: 
 ISPOR 14th Annual European Congress 2011, “Rational Health 
Care Decision Making in Challenging Economic Times”, Madrid, 
Spain, 5/11-8/11/2011 (Katharina Hintringer). 
 IST /Institute of Science and Technology Austria, introduces It-
self, Klosterneuburg, 08/11/2011 (Claudia Wild). 
 Lecture Evening and Panel Discussion, “Healthy from the Start – 
Possibilities for Promoting Mental Health in Early Childhood”, 
GKK Styria and Public Health Course at the Medical University 
Graz, 17/11/2011 (Roman Winkler as a participant in a panel discus-
sion). 
 4th European Public Health Conference, Copenhagen, Denmark, 
10.-12/11/2011 (Brigitte Piso, Roman Winkler) 
December: 
 Social Symposium, “How Can Social Progress Be Measured?”, 
HVB, Vienna, 02/12/2011 (Claudia Wild) 
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3 Scientific Co-operations 
EUnetHTA JA, WP7 Meeting, Valetta/Malta, 03.-04/03/2011 (Claudia Wild, 
Gerda Hinterreiter, Marisa Warmuth) 
EUnetHTA JA, WP1/EC Meeting, Paris/France, 21.-22/03/2011 (Claudia 
Wild) 
EUnetHTA JA, WP4 Meeting, Rome/Italy, 06.-07/04/2011 (Stefan Mathis) 
EUnetHTA JA, WP1 /JA 2 Preparatory Meeting, Brussels/Belgium, 
11/04/2011 (Claudia Wild) 
EUnetHTA JA, Plenary Assembly Meeting, London/UK, 25.-26/05/2011 
(Claudia Wild) 
EUnetHTA JA, WP7/WP6 POP & EVIDENT Database Interoperability 
Meeting, Paris/France, 06/09/2011 (Gerda Hinterreiter) 
EUnetHTA JA, WP4 Meeting, Vienna/Austria, 15.-16/09/2011 (Stefan 
Mathis) 
EUnetHTA JA, WP7 Meeting, Rome/Italy, 29.-30/09/2011 (Claudia Wild, 
Gerda Hinterreiter, Marisa Warmuth) 
EUnetHTA JA, WP6 Meeting, LBI-HTA Vienna/Austria, 13.-14/10/2011 
(Gerda Hinterreiter, Marisa Warmuth) 
EUnetHTA JA, WP1/EC Meeting, Warsaw/Poland, 05/10/2011 (Gerda 
Hinterreiter) 
EUnetHTA JA, WP1 /JA2 Contract Negotiation, Brussels/Belgium, 
15/11/2011 (Claudia Wild) 
EUnetHTA JA, WP1/JA 2 Meeting with Commissioner Dalli on establishing 
a European HTA network under article 15 of Directive 2011/24/EU, 
Gdansk/Poland, 08/12/2011 (Claudia Wild) 
EUnetHTA JA, Conference “HTA in national and cross-border healthcare 
in Europe”, Gdansk/Poland, 08.-09/12/2011 (Claudia Wild) 
EUnetHTA JA, WP7B/WP6 POP database development E-Meeting, 
14/01/2011, 11:00 - 12:30 (Gerda Hinterreiter) 
EUnetHTA JA, WP7B/WP6 POP database development E-Meeting, 
17/01/2011, 13:00 - 14:00 (Gerda Hinterreiter) 
EUnetHTA JA, WP7B/WP6 POP database development E-Meeting, 
21/01/2011, 11:20 - 13:30 & 14:00-14:20 (Gerda Hinterreiter) 
EUnetHTA JA, WP7B/WP6 POP database development E-Meeting, 
01/02/2011, 12:20 - 12:30 (Gerda Hinterreiter) 
EUnetHTA JA, WP7B/WP6 POP database development E-Meeting, 
04/02/2011, 11:00 - 13:10 (Gerda Hinterreiter) 
EUnetHTA JA, WP6 AP-CP E-Meeting, 23/02/2011, 14:30 - 15:00 (Gerda 
Hinterreiter) 
EUnetHTA JA, WP7B/WP6 POP database development E-Meeting, 
14/07/2011, 11:00 - 12:30 (Gerda Hinterreiter) 
13 EUnetHTA  
face-to-face meetings  
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EUnetHTA JA, WP7B/WP6 POP database development E-Meeting, 
19/08/2011, 11:00 - 13:00 (Gerda Hinterreiter) 
EUnetHTA JA, WP7B/WP6 POP database development, further steps E-
Meeting, 21/11/2011, 13:00 - 14:00 (Gerda Hinterreiter, Claudia Wild, Marisa 
Warmuth, Judit Erdös) 
EUnetHTA JA, WP1/EC E-Meeting, 26/01/2011, 13:00 - 15:00 (Claudia 
Wild) 
EUnetHTA JA, WP1/EC E-Meeting, 13/04/2011, 13:00 - 15:00 (Claudia 
Wild) 
EUnetHTA JA, WP1/JA 2 Task Force E-meeting, 06/05/2011, 13:00 - 14:30 
(Gerda Hinterreiter) 
EUnetHTA JA, WP1/EC E-Meeting, 15/06/2011, 13:00 - 15:00 (Claudia 
Wild) 
EUnetHTA JA, WP1/EC E-Meeting, 07/09/2011, 13:00 - 15:00 (Claudia 
Wild, Gerda Hinterreiter) 
EUnetHTA JA, WP1 /JA2 Preparatory E-Meeting, 14/11/2011, 13:00 - 15:00 
(Claudia Wild) 
EUnetHTA JA, WP1/EC E-Meeting, 16/11/2011, 13:00 - 15:00 (Claudia 
Wild) 
EuroScan Meeting, Vienna/Austria, 17.-18/03/2011 (Anna Nachtnebel) 
EuroScan Meeting, Oslo/Norway, 17.-18/11/2011 (Anna Nachtnebel) 
INAHTA, 19th Annual Meeting, Rio de Janeiro, Brazil, 29/06 - 01/07/2011 
(Marisa Warmuth) 
EUROCHIP – European Cancer Health Indicator Project, Work Package 7 
on Cancer Costs and Outcomes, Milan/Italy, 20/06/2011 (Anna Nachtnebel) 
Project cooperation with Drahtwarenhandlung, Hauptverband der Sozial-
versicherungen, Technical University of Vienna, VRVis Zentrum für Vir-
tual Reality und Visualisierung Forschungs-GmbH, FDW GmbH, Florian 
Endel and Executive Information Service GmbH. in the scope of the Pro-
ject IFEDH /Innovative Framework for Evidence-Based Decision-making in 
Healthcare (Ingrid Zechmeister-Koss) 
Prim. Univ. Prof. Dr. Leonhard Thun-Hohenstein, Director of the Univer-
sity Clinic for Child and Adolescent Psychiatry at the Christian Doppler 
Clinic Salzburg, in the scope of the evaluation project “Child and Adolescent 
Psychiatry Salzburg”. Evaluation Team Meeting at the University Clinic for 
Child and Adolescent Psychiatry at the Christian Doppler Clinic, Salzburg, 
05.02.2010, 18.03.2011, 15.04.2011 and 08.07.2011 (Roman Winkler) 
EU COST-Network “Childbirth Cultures, Concerns, and Consequences: 
Creating a Dynamic EU Framework for Optimal Maternity Care” (Roman 
Winkler) 
HTA Zentrum Bremen (Anna Nachtnebel):  
 Second-line chemotherapy with cabazitaxel (Jevtana®) for the 
treatment of castration-resistant metastatic prostate can 
7 EUnetHTA  
EC/WP1 
e-meetings  
2 EuroScan meetings 
1 INAHTA meeting 
1 EUROCHIP meeting 
national cooperations  
further international 
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 Abiraterone acetate (ZytigaTM) as 2nd-line therapy for the treat-
ment of metastatic castration-resistant prostate cancer after do-
cetaxel therapy  
Istituto Oncologico Veneto-IRCCS-Padova, Hepatobiliary and Liver Tran-
splantation Unit, University of Padova, Agenzia nazionale per i servizi sani-
tari regionali (Anna Nachtnebel):  
 Selective internal radiotherapy using yttrium-90 microspheres for 
primary and secondary liver malignancies 
Azienda Ospedaliera Universitaria Integrata Verona (Stefan Mathis-
Edenhofer): 
 Eribulin (Halaven®) as third- or late- line mono-therapy for ad-
vanced/metastatic breast cancer 
Agency for Health Technology Assessment in Poland (Katharina Hintrin-
ger, Stefan Mathis-Edenhofer) 
 Dasatinib (Sprycel®) for the 1st line treatment of Philadelphia 
chromosome positive chronic myeloid leukaemia in the chronic 
phase 
MEL / “Assessment of Individual Medical Services” (AUT) and NUB / 
“New Examination and Treatment Methods” (GER) Cooperation with the 
Medical Advisory Service of the Germany Social Health Insurances (MDS), 
Dr. Monika Lelgemann and Dr. Annette Busley, Germany (Claudia Wild)  
AOK Germany: 2nd Update of the online HPV vaccination decision-making 
help (www.hpv-entscheidungshilfe.de) in July 2011 (Brigitte Piso) 
For the mutual EU Project Submittal for the FP 7, the establishment of 2 
consortia was undertaken with numerous academic institutions in the EU in 
the field of HTA in Hospitals (Coordinator: Dr. Laura Sampietro-Colom, 
Hospital Clínic Barcelona) (Claudia Wild, Marisa Warmuth), as well as in 
the field of Health Economics (Coordinator: Prof. Dr. Hans Severens, Insti-
tute of Health Policy and Management, Erasmus University Rotterdam) 
(Ingrid Zechmeister-Koss). 
Mathis-Edenhofer, S. (2011): Co-authorship „Registerstudien bei Diabetes 
mellitus“, Dirk Müller, Dr. rer. pol. D. Müller Institut für Gesundheits-
ökonomie und Klinische Epidemiologie (IKGE) 
Cooperation with the University of Sheffield (UK), UMIT/Helmholtz Zen-
trum (Munich): Zechmeister-Koss, I., Ara, R., Ward, S., Stollenwerk, B. 
(2011): Have statins met our expectations? A comparison of expected health 
gains from statins with epidemiological trends in Austria. Journal of Public 
Health. Online first: DOI: 10.1007/s10389-011-0440-4. 
 
Cooperation with the “Agency for Quality and Accreditation in Health 
care” /Department for Development, Research and Health Technology 
Assessment in Zagreb/Croatia: Zechmeister-Koss, I., Huić, M. (2011): Vas-
cular-Endothelial-Growth-Factor Inhibitors (anti-VEGF) in the manage-
ment of diabetic macular oedema: a systematic review. Accepted in BMJ 
Ophthalmology on 23/10/2011. 
Cooperation with the EbM-HVB: Warmuth, M., Schumacher, I. und Mar-
inger, B. (2011). Efficacy and safety of treatments for varicose veins of the 
cooperations in 
collaboration as part of 
publication projects 
Annual Report 
2011 
70 LBI-HTA | 2012 
lower extremity HTA-Project Report No. 51. Vienna: Ludwig Boltzmann In-
stitute for Health Technology Assessment.  
The following external authors contributed articles (editorials) to the HTA-
Newsletter in 2011: 
 DI Dr. Wolfgang Habacher, DI Dr. Peter Beck, HEALTH - Insti-
tute for Biomedicine and Health Sciences JOANNEUM RE-
SEARCH Company, „Evidenzbasierte Versorgungsplanung - Für 
Österreich ein weiter Weg zur Machbarkeit” (HTA-Newsletter 94:1) 
 Prof. Dr. med. Oliver Razum, University Bielefeld, „Gesundheit 
von Schwangeren und Säuglingen mit Migrationshintergrund“ 
(HTA-Newsletter 95:1) 
 Dr. Markus Narath, Styrian Hospital Association (KAGes), „An 
der Zeitwende: Vom Ende des Durchschnitts und der Vollkosten-
rechnung?“ (HTA-Newsletter 96:1) 
 Dr. Wolfgang Becker-Brueser, Editor-in-Chief of arznei-
telegramm, „Die Neuerfindung von ASS gegen Krebs: Wenn Vor-
beugen so einfach wäre“, (HTA-Newsletter 97:1) 
 Dr. Annette Zentner, MPH, Special Field of Management in the 
Healthcare Sector, Technical University Berlin, „Relative Effective-
ness Assessments: Wird die Bewertung des Zusatznutzes von Arz-
neimitteln zur EU-Sache?“ (HTA-Newsletter 98:1) 
 Mag. Sylvia Groth, MAS and Mag. Ulla Sladek, Women’s Health 
Centre Graz, „Health Literacy: Von Null auf Hundert”, (HTA-
Newsletter 99:1) 
 Wolfgang Wagner, APA/Austria Press Agency, „FDA und EMA: 
Erklärungsbedarf: Die Arzneimittelbehörden agieren nur teilweise 
im Gleichklang. Mehr Information und Transparenz wäre not-
wendig“, (HTA-Newsletter 101:1) 
 Matthias Neyt, MSC, PhD, Belgian Health Care Knowledge Centre 
(KCE), Hans Van Brabandt, MD, Belgian Health Care Knowledge 
Centre (KCE) and Director of the Belgian Centre for Evidence-
Based Medicine (CEBAM), “Transcatheter aortic valve implanta-
tion (TAVI) for the treatment of severe aortic stenosis”, (HTA-
Newsletter 102:1) 
 
further collaboration 
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4 Other Activities 
In 2011, Claudia Wild lectured in the: 
 master’s course “Health Management” at the Carinthia University of 
Applied Sciences (13.-15/01/2011),  
 post-graduate course “Patient Safety and Quality in Health-  care” at 
the University of Vienna, Institute for Ethics and Law in Medicine 
(13/01/2011)  
 advanced course “Intensive Medicine” at the Upper Austrian Medi-
cal Chamber (OÖÄK) (12/11/2011) 
 master’s course “Health Sciences” at the Private University for 
Health Sciences, Medical Informatics and Technology (UMIT) in 
Hall in Tyrol (06/06/2011) and in Linz (10/11/2011) 
 master’s course “E-Health” at the FH-Joanneum University of Ap-
plied Sciences, Graz (21.-22/12/2011). 
Ingrid Zechmeister-Koss is a visting lecturer 
 in the bachelor studies programme “Biomedical Analytics” at the Vi-
enna University of Applied Sciences, where she instructed the mod-
ule “Healthcare and Health Economics”  
 in the master’s course “Biomedical Analytics” at the Vienna Univer-
sity of Applied Sciences, where she instructed the module “Health 
Economics” on 04.-05/03/2011 
 Ingrid Zechmeister-Koss further lectured in the master’s course 
“Economics” at the Vienna University of Business and Economics on 
15/11/2011, and as guest lecturer on the topic “Health Technology 
Assessment” in the master’s course “Health Sciences” of the UMIT 
in Vienna on 26/8/2011. 
Brigitte Piso taught at the Danube University Krems  
 Elective course “Health Policy, Distributive Justice and HTA” on 
4/04/2011 
 “Public Health, Epidemiology, EbM” in the master’s course Ad-
vanced Orthopedic Surgery on 18/11/2011 
Roman Winkler was a visiting lecturer at the Promente-Akademie, Vienna; 
Focus: Research and Scientific Methodology, as part of the “Psychotherapeu-
tic Preparatory Course” (08.-10/04/2010 / 17.-19/06/2011). 
 
In 2011, Claudia Wild reviewed manuscripts for the following journals: 
 Zeitschrift für Ärztliche Fortbildung und Qualität im Gesundheits-
wesen / ZEFQ (also member of the Scientific Advisory Group) 
 British Medical Journal (BMJ) 
 Health Policy 
 IntJTAHC 
 Pharmacoeconomics & Outcomes Research 
teaching 
expert & referee 
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Ingrid Zechmeister-Koss was engaged in reviewing for the: 
 Journal “Vaccine” 
 Journal of Public Health 
 British Medical Journal (BMJ) 
 “Belgian Health Care Knowledge Center (KCE)” and  
 Abstract rating for the scientific conference of the Austrian Society 
of Public Health (ÖGPH)  
Marisa Warmuth was engaged in reviewing for the British Journal of Can-
cer. 
Anna Nachtnebel was engaged in reviewing for Int JTAHC. 
The following bachelor diploma and master theses were supervised by senior 
researchers, and supported by library services in 2011: 
 Katharina Hintringer (UMIT – Universität für Gesundheitswissen-
schaften, Medizinische Informatik und Technik): Appraisal of the 
quality of written consumer health information for patients with 
chronic myeloid leukaemia - Claudia Wild  
 Michael Pohl (master’s course in the scope of the university train-
ing course for Public Health at the Medical University Graz): “Gen-
eral non-smoker protection law as a health-promoting intervention 
– an HTA to evaluate the effect on acute myocardial infarction”,  - 
Ingrid Zechmeister-Koss 
Ongoing supervision of doctoral dissertation:  
 Mag. Philipp Radlberger (WU Wien, doctoral studies in economic 
policy): Economic analysis in the field of psychiatric indications – 
Possibilities and problems with health economic methods, illus-
trated by the examples of child and youth psychiatry and alcohol 
therapy – Review of research proposal - Claudia Wild 
 
supervision of bachelor 
diplomas, master’s 
theses and doctoral 
dissertations 
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5 Outlook 
As far as content is concerned, the LBI-HTA will also be involved in a strong 
EU-wide cooperation in 2012. This is of major importance for small institu-
tions in small countries (and accordingly smaller financial means), in order 
to efficiently deal with HTA resources. This entails working in English, 
resp., bi-lingually. Approx. 30% of the LBI-HTA products / reports are al-
ready being written in English. In order to increase this share, national (Aus-
trian) decision-makers in particular need to be convinced of also reading / ac-
cepting papers that are not written in German. 
As already in the “Early Assessment of New Oncologica” and the “Assess-
ment of Medical Hospital Services Prior to Inclusion in the Benefits Cata-
logue Using GRADE”, the LBI-HTA will continue to work consequently on 
methodological consolidation in the assessment of “complex interventions”. 
Beyond that, the year 2012 – after the letters of intent have been received – 
will be dedicated to the concrete negotiation of framework conditions of the 
LBA-HTA 2013+ work programme. 
 
EU-wide cooperations 
Profile building through 
methodological 
expertise 
negotiation of the LBI-
HTA 2013+  
